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Abstract 
Non-severe hypoglycemia (NSH) is a common, adverse event arising from the use of 
insulin/secretagogues to treat type 2 diabetes mellitus (T2DM). This thesis explored risk 
indicators for the frequency of any NSH, daytime NSH, and nocturnal NSH where 
outcomes were regarded as event counts and ordinal categories. Real-world data used in 
this thesis was provided by a population-based sample of Canadian adults with T2DM on 
insulin and/or secretagogues from the InHypo-DM Study. Count and ordinal outcomes 
were analyzed using negative binomial regression models and a proportional odds model, 
respectively. Backward selection was applied to both modelling approaches. Younger age, 
lower annual household income, being employed, longer duration of diabetes, higher 
HbA1c, having comorbidities were associated with an increased frequency of any NSH. 
Similar risk indicators were noted for daytime and nocturnal NSH. These findings may be 
used to identify patients at higher risk for NSH, creating opportunities to prevent 
hypoglycemia.    
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Hypoglycemia, type 2 diabetes mellitus, real-world, risk indicators, socio-demographic, 
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Chapter 1  
1 Introduction 
The purpose of this chapter is:  
1) To present the rationale for this thesis 
2) To outline the objectives of this thesis    
1.1 Thesis Rationale and Objectives 
Optimal management of Type 2 Diabetes Mellitus (T2DM) seeks to achieve glycemic 
control and often includes medications such as insulin or insulin secretagogues. These 
medications aim to reduce high blood glucose levels, the hallmark feature of diabetes. 
However, hypoglycemia is a common adverse event associated with the use of insulin 
and/or insulin secretagogues. Thus it is often a major barrier to attaining optimal glycemic 
control. Hypoglycemia is characterized as non-severe when a patient can effectively self-
manage to resolve symptoms while severe hypoglycemia (SH) requires third-party 
assistance.  
Despite the focus of literature on SH, non-severe hypoglycemia (NSH) remains a 
significant concern among individuals with diabetes. Non-severe hypoglycemia occurs 
more frequently than SH1–3. It has also been implicated as an independent predictor of 
future SH3–5. However, the burden of NSH may be underestimated as it is clinically 
underappreciated and often under-reported6. Historically, hypoglycemia is considered a 
major concern for Type 1 Diabetes Mellitus (T1DM), but not T2DM7. The incidence of 
hypoglycemia is greater in T1DM8 however, individuals with T2DM account for 90% of 
all people with diabetes9. Hence, the absolute burden of NSH is much greater for T2DM 
compared to T1DM at a population level. In addition, the risk of hypoglycemia among 
patients with T2DM also increases with duration of disease, nearing the incidence rates 
observed in T1DM1,10. Thus, further research on NSH in T2DM is needed to expand the 
evidence base, identify populations at increased risk of NSH and recognize upstream risk 
indicators for SH.  
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Much of the literature on hypoglycemia has come from clinical trials. However, such 
studies are designed with stringent inclusion criteria that often excludes individuals at 
highest risk of hypoglycemia, thus limiting the generalizability of results. But with the 
advancement of technology, large data sources beyond the traditional clinical settings have 
emerged and present opportunities to complement trial-based research with “real-world 
studies”. These studies generate real-world evidence based on “information on health care 
that is derived from multiple sources outside typical clinical research settings”11. Real-
world data sources may include “electronic health records, claims and billing data, 
product and disease registries, and data gathered through personal devices and health 
applications”11. Yet, poor documentation of hypoglycemia in clinical practice is a major 
limitation for the use of certain real-world data sources, namely electronic health records 
and insurance claims/billing data. This issue is particularly relevant to NSH as these events 
are self-managed and do not require assistance from healthcare providers. In light of these 
challenges, the InHypo-DM Study (formally entitled “UnderstandINg the Impact of 
Hypoglycemia on Diabetes Management: A Survey of Perspectives and Practices”) can 
offer real-world evidence regarding NSH as self-reported hypoglycemia data was collected 
in a non-clinical setting.  
The InHypo-DM Study, an investigator-initiated study funded by Sanofi Canada, is the 
largest population-based inquiry of hypoglycemia in Canada to date. Led by Dr. Stewart 
Harris, this study sought to determine the real-world epidemiology of hypoglycemia, 
which encompassed the ascertainment of real-world incidence and factors influencing 
hypoglycemia management behavior among individuals with Diabetes Mellitus, 
significant others, and healthcare providers. The three main objectives of the InHypo-DM 
Study involving individuals with Diabetes Mellitus were: 1) to quantify the complex 
factors contributing to sub-optimal hypoglycemia management behaviour; 2) to ascertain 
the real-world, self-reported incidence of hypoglycemia; and 3) to evaluate the socio-
demographic and clinical factors associated with hypoglycemia frequency. Given the 
paucity of research on NSH, this thesis seeks to address the third objective of the InHypo-
DM Study by exploring the socio-demographic and clinical risk indicators associated with 
NSH in T2DM.  
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In epidemiological research, regression models are commonly used to identify risk 
indicators of health outcomes. The selection of regression models used in analysis is 
dependent on the data type of the model’s outcome (e.g., dichotomous, count, ordinal, 
etc.). For this thesis, hypoglycemia frequency would be the outcome in the regression 
models. Among the various data types used in the literature, hypoglycemia frequency is 
commonly expressed in absolute terms as a count outcome (i.e., the number of events). 
However, the clinical significance of comparing absolute frequencies of hypoglycemia, as 
conveyed by a count outcome, remains debatable on both a population- and individual-
level. To illustrate, it is difficult to interpret whether a population that experienced an 
average of three events within the past month (or on an individual-level, a patient who 
experienced three events) compared to a population that had four events (likewise, a 
patient with four events) within the same timeframe merits public health or clinical 
attention. Similarly, the clinically-significant difference between those who had three 
events versus those who had six events within the past month is arguable, especially given 
the known recurrence of NSH12.  
Thus, this thesis also sought to enhance the clinical interpretation of NSH frequency and 
consequently, results gleaned from regression models that characterize the association of a 
risk indicator to the frequency of NSH. The categorization of data into meaningful 
categories is a common approach used in clinical epidemiology to enhance clinical 
interpretation. A prime example of this is the classification of Framingham Risk Scores 
into categories that convey one’s 10-year coronary heart disease risk ranging from ‘very 
low’ to ‘very high’13. This line of reasoning was the rationale for the fourth objective in 
this thesis. Thus to strengthen the clinical interpretation of results in this thesis, the count 
outcome of NSH frequency was categorized into an ordinal outcome with categories 
proposed to be clinically relevant. 
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Given the overarching aim of exploring risk indicators for NSH, the specific objectives of 
this thesis were: 
1) To identify socio-demographic and clinical risk indicators associated with the 
frequency of any NSH (daytime and nocturnal events) among adults with T2DM 
2) To identify socio-demographic and clinical risk indicators associated with the 
frequency of daytime NSH among adults with T2DM 
3) To identify socio-demographic and clinical risk indicators associated with the 
frequency of nocturnal NSH among adult with T2DM  
4) a) To propose a set of clinically-relevant categories, using an informed approach 
(i.e., not driven by the distribution of data), that classify NSH frequency 
b) To re-conduct Objective 1 where the dependent variable of ‘frequency of any 
NSH’ is treated as an ordinal outcome with categories proposed in Objective 4a 
rather than a count outcome (as done in Objective 1). 
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Chapter 2  
2 Literature review 
The purpose of this chapter is to provide contextual information regarding: 
1) Diabetes Mellitus, with a focus on T2DM (Section 2.1) 
2) The definition, classification, epidemiology, and impact of hypoglycemia with a 
focus on NSH (Section 2.2) 
3) Current findings, limitations, methodological considerations of research on risk 
indicators for NSH (Section 2.3) 
2.1 Diabetes mellitus 
Diabetes Mellitus is a chronic, metabolic disease characterized by hyperglycemia (high 
blood glucose levels) due to the body’s inability to produce or effectively use insulin. 
Common symptoms include frequent urination, excessive thirst, hunger, and blurry vision. 
Chronic hyperglycemia in diabetes can have long-term health consequences. 
Microvascular complications can inflict damage to the kidneys14, nerves15, and eyes. 
Nephropathy can lead to kidney failure while neuropathy can induce foot ulcers where 
extreme cases may lead to amputation. Diabetic retinopathy is a serious complication that 
can lead to vision loss and blindness16,17. Macrovascular complications, such as 
cardiovascular disease, are attributed to diabetes18. In fact, cardiovascular disease is the 
leading cause of death among individuals with diabetes, accounting for 44% of deaths in 
patients with T1DM and over 50% of deaths in T2DM globally19. Furthermore, diabetes 
negatively impacts mental health20 and imparts a substantial economic burden21.   
Diabetes is a cause for concern at both the national and global level. In Canada, the 
prevalence of diabetes among Canadians (over the age of 1) in 2008 was approximately 
2.4 million and is projected to reach 3.8 million by 201922. The International Diabetes 
Federation estimates that the global prevalence of diabetes among adults will increase 
from 8.8% in 2015 to 10.4% (approximately 415 million individuals) by 204023. 
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2.1.1 Type 1 vs. Type 2  
Based on etiology, there are two major classes of Diabetes Mellitus: Type 1 and Type 2. 
Type 1 Diabetes Mellitus is characterized by insulin deficiency. It is an autoimmune 
disorder in which the body cannot produce insulin because of immune-mediated 
destruction of the insulin-secreting beta cells found in the pancreas. Type 2 Diabetes 
Mellitus is characterized by insulin resistance and relative insulin deficiency. Unlike 
T1DM, pancreatic beta cells in patients with T2DM can secrete insulin but the body is 
unable to effectively use insulin (a phenomenon known as relative insulin resistance). 
However, progressive failure of beta cells to secrete insulin occurs as T2DM advances. 
Thus, the pathophysiology of late-stage T2DM may resemble T1DM where beta cells 
cannot produce endogenous insulin. As a result, clinical management of advanced T2DM 
requires insulin, much like T1DM.  
2.1.2 Management of type 2 diabetes mellitus  
Currently, there is no cure for T2DM. Management of diabetes focuses on reducing 
hyperglycemia to achieve optimal glycemic control. The gold standard measure of glucose 
control is the level of glycated hemoglobin A1c (HbA1c), which indicates average blood 
glucose levels over the past three months24. Clinical management of most patients with 
T2DM aims for a target HbA1c level of ≤ 7.0%25.  Based on the Diabetes Canada Clinical 
Practice Guidelines, T2DM is initially managed through lifestyle modifications, such as 
physical activity and dietary changes26. If these lifestyle changes fail to achieve HbA1c 
targets within 2-3 months, diabetes medications are incorporated into management to 
lower blood glucose levels. Table 1 details the various classes of diabetes medications, 
which differ by pharmacological mechanism. Metformin, a type of biguanide, is the most 
frequently used first-line treatment for diabetes26,27. If monotherapy is unable to achieve 
glycemic targets, dual and triple therapy are subsequently considered. It is recommended 
that combination therapy involves various classes of drug so they can exert different 
pharmacological action to lower hyperglycemia28. 
 
   
7 
 
Table 1. Classes of diabetes medication available for the management of T2DM. Adapted 
from the Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and 
Management of Diabetes in Canada26  
Drug class Pharmacological Action Risk of hypoglycemia 
Alpha-glucosidase 
inhibitor 
Slows absorption of glucose  
Biguanide (most common 
drug being Metformin) 
Reduces hepatic glucose 
production and enhances insulin 
sensitivity in peripheral tissues 
 
DPP-4 inhibitors 
Inhibits the breakdown of 
incretins, leading to increased 
postprandial insulin production 
and decreased glucagon secretion 
 
GLP-1 receptor agonists 
Stimulates insulin secretion and 
inhibits glucagon secretion 
 
Insulin 
Acts as an exogenous source of 
insulin; promotes glucose uptake 
from the bloodstream 
✓ 
Insulin secretagogues  
(i.e., sulfonylureas, 
meglinitides) 
Stimulates insulin secretion in a 
glucose-independent fashion 
✓ 
SGLT-2 inhibitors 
Enhances elimination of glucose 
via urine  
 
Thiazolidinediones (TZD) 
Enhances insulin sensitivity in the 
liver and peripheral tissues 
 
 
   
8 
 
Among these drug classes are exogenous insulin and insulin secretagogues, which are the 
only medications that can independently induce hypoglycemia. Exogenous insulin acts in 
the same manner as the endogenous insulin hormone produced by the body to increase 
glucose uptake from the bloodstream. Insulin secretagogues, which include sulfonylureas 
and meglinitides, stimulate pancreatic beta cells to secrete insulin. Meglinitides have a 
faster, but shorter duration of action than sulfonylureas28. Pharmacological management of 
T2DM requires consideration of various factors including the effectiveness of lowering 
blood glucose, weight gain, and safety considerations of hypoglycemia risk.  
2.2 Hypoglycemia  
Hypoglycemia is an adverse event characterized by abnormally low levels of blood glucose. 
It can occur among patients with T2DM using insulin and/or insulin secretagogues (i.e,. 
sulfonylureas and meglinitides)9 as these medications are not sensitive to ambient blood 
glucose levels and may consequently lower blood glucose past euglycemic (normal glucose) 
levels29. Sulfonylureas have been a mainstay of oral medication for T2DM for nearly fifty 
years30. They continue to be one of the most commonly prescribed oral glucose-lowering 
therapies given its low cost31. In Ontario, Canada, it was the second most common diabetes 
medication used (after metformin) by patients with diabetes (>65 years old) based on data 
available up to 201327. Insulin is often prescribed to patients with T2DM as beta cell failure 
occurs in the later stages of the disease.  
As such, a delicate balance exists between achieving target glycemic levels and preventing 
medication-induced hypoglycemia. Seminal studies (i.e., UKDPS, ACCORD, 
ADVANCE, VADT study) on T2DM management illustrated that hypoglycemia remains 
a substantial safety concern despite the cardiovascular benefits of achieving glycemic 
target29,32–34. In each of these large-scale trials, intensive therapy was associated with a 
significant increase in the risk for hypoglycemia among patients with T2DM, which was 
further confirmed by a meta-analysis of the studies32. Similarly, a global study revealed 
that 76% of physicians indicated that concern for hypoglycemia prevented them from 
managing their patients with diabetes more aggressively35. Furthermore, nearly 80% of 
physicians in that study acknowledged that they “must manage safety and efficacy but it is 
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difficult to optimally manage both with insulin”36.  Indeed, the risk of hypoglycemia poses 
as a barrier to the optimal management of diabetes. 
2.2.1 Clinical definition and categories of hypoglycemia 
The Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and 
Management of Diabetes in Canada37 defined hypoglycemia by three characteristics 
known as Whipple’s Triad:   
1) The development of autonomic or neuroglycopenic symptoms 
2) A low plasma glucose level of <4 mmol/L (72 mg/dL) for people with diabetes 
treated with insulin or an insulin secretagogue 
3) Symptoms responding to the administration of carbohydrates  
Physiological mechanisms are in place to counteract decreasing blood glucose levels. First, 
insulin secretion is decreased to reduce glucose uptake from the bloodstream. Second, the 
counter-regulatory hormone, glucagon, is released to promote glucose release from the 
liver into the bloodstream if glucose levels continue to decrease. Third, the adrenal 
medulla secretes epinephrine to increase blood glucose levels. If these mechanisms cannot 
restore normal glucose levels, stronger sympathetic adrenal and neural activation induces 
symptoms of hypoglycemia to prompt the behavioral response of carbohydrate 
consumption.  
Symptoms of hypoglycemia are classified as autonomic or neuroglycopenic. Autonomic 
symptoms are the result of sympathetic neural activation signaling the physiologic changes 
induced by hypoglycemia. These include palpitations, tremblings, anxiety, sweating, 
hunger, nausea, and paresthesias (tingling, burning sensation on the skin)37. 
Neuroglycopenic symptoms are trigged by the brain’s deprivation of glucose. These can 
manifest as dizziness, headaches, drowsiness, weakness, vision changes and cognitive 
impairments (confusion, difficulty concentrating or speaking)37. Unconsciousness, 
seizures, and comas may occur in severe cases.    
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Hypoglycemia is classified based on its severity, which involves the type of symptoms and 
extent of management needed to resolve symptoms37. Table 2 details this classification 
system. Non-severe hypoglycemia, comprising of mild and moderate events, is 
distinguished from severe hypoglycemia based on self-treatment being sufficient to 
resolve an episode. Guidelines published by Diabetes Canada recommend that non-severe 
(mild/moderate) hypoglycemia can be self-treated with the oral ingestion of 15g of 
carbohydrates (e.g., glucose tablets, juice, hard candies)37. Severe hypoglycemia in a 
conscious individual can be resolved through oral ingestion of 20g of carbohydrates, 
assisted by a third-party individual. Severe hypoglycemia with loss of consciousness 
requires intervention by healthcare professionals where a subcutaneous/intramuscular 
injection of glucagon or an intravenous injection of glucose is administered.   
Furthermore, hypoglycemia can be categorized by time of occurrence38, though clinical 
guidelines have not included formal definitions for these categories. The typical working 
definition for nocturnal hypoglycemia refers to events occurring during sleep or between 
bedtime and breakfast while events occurring during waking hours are termed daytime 
hypoglycemia6,39. Nocturnal hypoglycemia can be particularly dangerous as it may reduce 
the responses of patients with T2DM to awakening, thus delaying treatment for low blood 
glucose40.  
Table 2. Classes of hypoglycemia severity, as defined by the Diabetes Canada 2018 
Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada26 
Severity  Criteria 
Mild Autonomic symptoms are present. The individual is able to self-treat. 
Moderate Autonomic and neuroglycopenic symptoms are present. The individual is 
able to self-treat. 
Severe Individual requires assistance of another person. Unconsciousness may 
occur. Plasma glucose is typically <2.8mmol/L.  
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2.2.2 Incidence of hypoglycemia in T2DM 
Occurrence of hypoglycemia is most accurately reflected as incidence given the acute 
nature of this adverse event. Specifically, the American Diabetes Association recommends 
that hypoglycemia should be reported as an incidence proportion and rate38. Incidence 
proportion indicates the proportion of individuals who experience at least one 
hypoglycemia event within a certain timeframe. Incidence rate (i.e., number of 
hypoglycemia events per person-time) conveys the frequency of events, offering insight 
into the recurrent nature of hypoglycemia.  
As shown by clinical trials and observational studies, NSH has a higher incidence 
proportion and rate compared to SH among patients with T2DM1,8,12,41–43. However, the 
incidence of hypoglycemia is typically underestimated by clinical trials compared those 
reported in real-world studies44. In a recent systematic review and meta-analysis of 46 
real-world, population-based studies12, Edridge et al. found a higher incidence of NSH 
than SH among patients with T2DM on any type of diabetes medications. Results are 
detailed in Table 3. Furthermore, crude hypoglycemia incidence from the InHypo-DM 
Study are relevant as that study served as the data source for this thesis. Again, these 
findings revealed that adults with T2DM on insulin and/or insulin secretagogues had a 
higher self-reported incidence of NSH than SH45. These estimates are detailed in Table 3.  
Table 3. Hypoglycemia incidence among individuals with T2DM as reported by Edridge 
et al. (2015)12 and Ratzki-Leewing and Harris et al. (2018)45   
 Severity of 
Hypoglycemia 
Incidence 
Proportion (%) 
Incidence Rate         
(events per person-years) 
Edridge et al. 
(2015) 
Non-severe  
(n = 4083) 
45%a 
(95% CI: 34 to 57%) 
19.03 
(95% CI 0.00 to 51.08)b 
Severe 
(n = 528,310) 
6%a 
(95% CI: 5 to 7%)  
1.05  
(95% CI: 0.00 to 3.69)b 
Ratzki-
Leewing and 
Harris et al. 
(2018) 
Non-severe 
(n=456) 
54%c 
(95% CI: 50 to 59%) 
27.95 
(95% CI: 27.46 to 28.44) 
Severe  
(n=456) 
38%d 
(95% CI: 33 to 42%) 
2.45 
(95% CI: 2.31 to 2.60) 
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aFollow-up period for NSH (8 studies) ranged from one to 10.5 months. Follow-up period for SH 
(40 studies) ranged from one month to 22 years. Authors determined that follow-up period was not 
a significant predictor of incidence proportion in NSH/SH based on a meta-regression.  
bAuthors truncated any lower bounds of the 95% CI which extended into negative values to 0.00 
c30-day incidence proportion 
d1-year incidence proportion 
2.2.3 Impact of hypoglycemia 
2.2.3.1 Physiological impact 
Hypoglycemia has been linked to an increased risk of cardiovascular disease and 
events46,47. In a population-based study of insulin-treated patients with diabetes, 
hypoglycemia was associated with an increased risk of composite cardiovascular (CV) 
events consisting of myocardial infarction, stroke, or cardiovascular death48. Furthermore, 
hypoglycemia was also implicated as an independent predictor of all-cause mortality48. 
The Action to Control Cardiovascular Risk in Type 2 Diabetes (ACCORD) trial, which 
examined the effect of intensive therapy (target HbA1c: < 6%) on reducing CV events 
compared to standard therapy (target HbA1c: 7 to 7.9%) in T2DM, was halted early due an 
increased death rate in the intensive-therapy arm34. Interestingly, post-hoc analyses found 
that hypoglycemia was a significant risk factor of death in both treatment groups of 
patients with T2DM49.   
Hypoglycemia unawareness is a physiological phenomenon that can develop as T2DM 
progresses9. Recurrent episodes of hypoglycemia can induce hypoglycemia unawareness, 
creating a vicious cycle of subsequent events. Individuals with hypoglycemia unawareness 
cannot detect the characteristic autonomic symptoms of NSH. They only gain awareness 
of their low blood glucose levels at the onset of neuroglycopenic symptoms (i.e., moderate 
hypoglycemia) or when self-management is not possible (i.e., severe hypoglycemia). This 
condition is a result of the blood glucose threshold for autonomic symptoms being lowered 
towards the threshold for neuroglycopenic symptoms50. Fortunately, hypoglycemia 
unawareness can be prevented and reversed by strict avoidance of hypoglycemia51.  
Hypoglycemia, both non-severe and severe, can impair driving and potentially lead to 
motor accidents52–55. Importantly, moderate hypoglycemia has been noted as the most 
common reason for impaired driving among diabetes patients54. Healthcare providers in 
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most Canadian jurisdictions must notify transportation authorities if they are clinically 
suspicious of patients whose driving can be impaired by hypoglycemia56. As a result, 
patients may withhold or underreport hypoglycemia to their healthcare providers out of 
fear of their driving privileges being revoked.   
2.2.3.2 Psychological impact 
Hypoglycemia, even in its mild form, can induce a substantial burden of fear among 
patients with T2DM related to experiencing subsequent episodes57. Fear of hypoglycemia 
can influence patients to adopt risky self-management behaviors in hopes of avoiding 
future events58,59. The occurrence and fear of hypoglycemia are common reasons for 
medication non-adherence among patients with T2DM59. In a Canadian study, 43% and 
58% of adults with T2DM reduced their insulin intake following an event of NSH and SH, 
respectively57. In doing so, patients with diabetes demonstrate that the psychological 
burden of hypoglycemia can outweigh their concern for the micro- and macrovascular 
consequences of their disease in the long run38. Interestingly, fear of hypoglycemia has 
been associated with increased rates of hypoglycemia60 and negatively impacts the quality 
of life of patients with T2DM61,62. 
2.2.3.3 Economic impact  
Hypoglycemia has a negative economic impact on the healthcare system and individual 
patients. In Canada, hypoglycemia among insulin- or sulfonylurea-treated patients with 
T2DM incurs an annual cost of $65.5 million on the healthcare system63. Canadian 
patients with T2DM have reported an annual out-of-pocket spending of $149 CAD on 
average to treat their hypoglycemia64.  As expected, severe hypoglycemia imparts a 
financial burden as it may involve emergency department visits or hospitalizations65,66. 
However, a recent economic analysis (taken from a US healthcare payer perspective) 
found that the total annualized cost of NSH is greater than SH ($89 vs. $43) among 
patients with T2DM65. This was attributed to the substantially higher incidence rate of 
NSH compared to SH1. Non-severe hypoglycemia also contributes to an increase in blood 
glucose monitoring following an event58,67, indirect costs in the form of work 
absenteeism58,67,68 and lowered work productivity among patients with T2DM58,65,67,68.   
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It is evident that NSH contributes to the physiological, psychological, humanistic and 
economic burden on patients with T2DM. Although NSH does not require third-party 
assistance, the compelling evidence presented suggests that NSH is clinically important 
and should not be overlooked.  
2.3 Risk indicators for hypoglycemia  
Risk indicators refer to both factors that are causally related (i.e., risk factors) and factors 
that are non-causally associated (i.e., risk markers) with “a change in the risk of a relevant 
health process, outcome, or condition”69. The term “risk indicator” will used to describe the 
potential socio-demographic and clinical characteristics of NSH being explored in this thesis 
as causality was not examined.  Currently, most of the existing literature on hypoglycemia 
has focused on SH and its associated risk factors, a trend that is illustrated by the multiple 
reviews summarizing studies on risk factors for SH in patients with T2DM41,70,71. On the 
other hand, the evidence base for NSH and its risk indicators is under-developed. This is 
reflected in the 2013 and 2018 Diabetes Canada Clinical Practice Guidelines where risk 
factors for SH, but not NSH, were detailed37,72.  
The lack of research on NSH may be explained by several reasons. Historically, NSH has 
been clinically underappreciated compared to SH given its less overt symptoms and lack 
of third-party assistance required for treatment. In addition, occurrence of NSH is more 
difficult to capture than SH although it is more frequently experienced by patients with 
T2DM. Non-severe hypoglycemia is less likely to be noted in medical records as patients 
with T2DM seldom self-report events to healthcare providers and healthcare providers 
often do not ask about these events during routine clinic visits6,58,67. In Canada, only 15% 
of patients with T2DM told their doctors about NSH at their next routine visit after 
experiencing an event59. Conversely, SH is more likely to be documented, though still 
underestimated, in electronic medical records or administrative databases as management 
can involve visits to the emergency department or hospitalization. In cases of SH that are 
resolved outside the healthcare system, events can also be confirmed by third-party 
individuals (i.e., family/friends) who may have provided the external assistance needed to 
treat SH.  
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2.3.1 Findings/limitations of current literature  
Our current understanding of NSH and its risk indicators have mostly come from clinical 
trials where hypoglycemia is a conventional safety outcome used to compare diabetes 
medications73. However, the generalizability of results gleaned from clinical trial data for 
hypoglycemia is limited for various reasons. First, the stringent eligibility criteria used 
often involve exclusion criteria such as presence of hypoglycemia unawareness and a 
history of hypoglycemia74. Older patients with T2DM are also often excluded75 despite the 
additional challenges they face, like frailty and comorbidity, making this population more 
vulnerable to the risk and consequences of hypoglycemia76. Thus, individuals who are 
likely at greatest risk for hypoglycemia are underrepresented or not captured entirely by 
the sampling frames used in clinical trials. Second, investigations of risk indicators for 
hypoglycemia from clinical trials are usually conducted as secondary analyses41,77. As 
such, attrition bias can be introduced into these studies as individuals lost to follow-up 
may have been those who experienced more frequent events of hypoglycemia78. This can 
have pertinent implications for determining risk indicators as those who remained in the 
trial may have been individuals at lower risk for hypoglycemia. As well, issues with 
statistical power may occur as clinical trials are designed to have sufficient power in 
detecting an effect difference between randomized arms, but not necessarily to identify 
significant risk indicators, though meta-analyses may address this limitation78. 
Schopman et al. conducted a systematic review and meta-analysis of 25 clinical trials 
which not only explored risk factors for SH, but also mild hypoglycemia among patients 
with T2DM using insulin and sulfonylurea41. Mild hypoglycemia was defined an event 
with a blood glucose level <3.1mmol/L that could be self-treated. Data was extracted from 
the intervention arm of sulfonylurea and once-daily or twice-daily insulin therapy in 
clinical trials that were compared to GLP-1 agonists or DPP-4 inhibitors. The authors 
intended to explore age, duration of diabetes, baseline HbA1c levels, and change in HbA1c 
levels as potential risk factors for mild hypoglycemia using a stepwise multivariable meta-
regression. However, this statistical analysis could not be performed as none of the 
potential risk factors reached the predefined alpha level of 0.25 in univariate analyses. 
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Thus, none of these characteristics could be identified as risk factors for having at least 
one mild hypoglycemic event.   
Observational studies have also been conducted to understand risk factors for 
hypoglycemia among T2DM. However, several methodological limitations are common to 
these studies. First, some defined a study population of T2DM individuals without any 
specification on the type of diabetes medication used42,79–81. This sampling frame may 
have resulted in the inclusion of T2DM individuals who were exclusively on medications 
that cannot independently induce hypoglycemia (i.e., all medication types listed in Table 2 
except for insulin and/or secretagogues) and thus, were not truly at risk. Second, these 
studies often aggregated NSH and SH into a composite outcome of “any hypoglycemia” 
when determining risk factors8,12,81–84. In doing so, these studies make an implicit 
assumption that risk factors of NSH and SH are the same. However, evidence suggests 
otherwise3. Although NSH accounts for most events occurring in these studies that 
consider “any hypoglycemia”, the identification of risk factors or more broadly, risk 
indicators, for NSH is precluded without the distinction between non-severe and severe 
events. Thus, there is a need to understand of NSH, specifically, and address these 
methodological limitations. 
A limited number of observational studies have been conducted with a particular focus on 
NSH. Four studies that have explored potential socio-demographic and/or clinical risk 
factors for NSH among T2DM are detailed below. Their results are also summarized in 
Table 4. 
1) The multinational, cross-sectional PANORAMA study consisted of 5,783 patients with 
T2DM ≥ 40 years old42. In this study, Simon et al. sought to identify risk factors for 
mild hypoglycemia, which was defined as a hypoglycemia event occurring in the past 
year that did not require external assistance (i.e., self-treated). Using a logistic 
regression with a stepwise selection procedure, the independent risk factors identified 
among patients with T2DM for experiencing at least one event of mild hypoglycemia 
were: female gender, longer duration of diabetes, self-monitoring of blood glucose, 
lower HbA1c levels, and medication types (specifically, oral hypoglycemia agents with 
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sulfonylurea, oral hypoglycemic agents with glinides, insulin with or without oral 
hypoglycemic agents).    
2) In a prospective cohort study by Sonoda et al., social, lifestyle and clinical 
characteristics were captured at baseline from 123 insulin-treated Japanese patients 
with diabetes85. The occurrence of mild hypoglycemia, defined as a blood glucose 
level of 50 to 69 mg/dl (i.e., 2.8 to 3.8 mmol/L), was recorded prospectively for six 
months. Authors used a multinomial logistic regression to compare those who only 
experienced mild hypoglycemia, experienced severe hypoglycemia, and those who did 
not experience any hypoglycemia. Results identified presence of “assistance from 
family members at an insulin injection” as the only independent predictor for 
experiencing at least one event of mild hypoglycemia within six months.  
3) The online, cross-sectional Global Attitude of Patients and Physicians (GAPP2) study 
was conducted in six countries including Canada86. The sample of 3,042 patients with 
T2DM on basal insulin was recruited from research panels that were representative of 
the online population for each respective country. The authors, Brod et al., used a Chi-
squared Automatic Interaction Detection analysis, which involves sorting variables 
into sequential nodes on a decision tree based on the most highly significant 
associations to identify risk factors of self-treated hypoglycemia within the last 30 
days. Unlike studies employing regression methods, the risk factors identified were not 
independent predictors, but characteristics of the subgroup with the highest self-treated 
hypoglycemia incidence. Results found that this subgroup comprised of patients with 
T2DM who were treated with a basal-bolus insulin regimen and experienced the most 
worry about having hypoglycemia (i.e., 6-9 occasions of worry).  
4) In a cross-sectional study of patients with T2DM, Gu et al. explored non-linear 
associations between potential clinical risk factors for mild hypoglycemia using a 
logistic regression with restricted cubic splines87. Their study sample consisted of 
6,633 patients with T2DM on a basal-bolus insulin regimen who did not have a history 
of third-party assisted SH within the past three months. Gu et al. defined mild 
hypoglycemia as symptomatic hypoglycemia with palpitations, hunger, sweating, 
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tremulousness, weakness, fatigue, dizziness, or anxiety within the past month. They 
noted that lower BMI and use of SMBG were linearly associated with increased risk of 
mild hypoglycemia. There was a non-linear association with increased risk of mild 
hypoglycemia for several clinical risk factors including: age ≥ 40 years, a duration of 
diabetes of 2 to <6 years, HbA1c levels between 7-11.5%, triglyceride levels between 
1.7-3.6 mmol/L, low-density lipoprotein cholesterol levels between 2.6-4.8 mmol/L, 
and high-density lipoprotein cholesterol of 1.2-4.8 mmol/L. 
Table 4. Socio-demographic/clinical risk factors associated with the increased risk of NSH 
in T2DM, as identified in the literature 
• Older age (≥ 40 years old)87  
• Female gender42 
• Duration of diabetes 
o Longer duration of diabetes42 
o Duration of diabetes ≥2 to <6 years87 
• Use of SMBG42,87 
• HbA1c  
o Lower HbA1c42 
o HbA1c of ≥7 to <11.5%87 
• Medication type42  
o Insulin with or without OHA 
o Glinide with OHA 
o Sulfonylurea with OHA 
• Basal-bolus insulin regimen and worry about hypoglycemia*86 
• Lower BMI87 
• Triglyceride level between 1.7 to 3.5 mmol/L87 
• LDL-C between 2.6 to 4.8 mmol/L87 
• HDL-C between 1.2 to 4.8 mmol/L87 
• Mean arterial pressure ≥90 to <110 mmHg87 
• Assistance from family members for insulin injections85 
• Current drinker85  
*Brod et al. 201286 identified this combination of characteristics as most strongly 
associated with the incidence proportion of NSH using Chi-Squared Automatic Interaction 
Detection; these are not independent risk factors   
Abbreviations: BMI: body mass index: HbA1c: hemoglobin A1c; HDL-C: high-density 
lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; OHA: oral 
hypoglycemic agents; SMBG: self-monitoring blood glucose 
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2.3.2 Statistical considerations 
Statistical methods used for analyses of hypoglycemia data in the literature are diverse. 
The occurrence of hypoglycemia has been handled as various data types ranging from a 
count60,82,84,88, dichotomous42,83,85,87 to categorical (ordinal)8,89,90 outcome. Appendix A 
highlights several observational studies to illustrate the varying data types used to describe 
hypoglycemia occurrence and the various analytical techniques used to explore risk 
factors. Hypoglycemia reported as a count outcome indicates the absolute frequency of 
events whereas a dichotomous outcome often denotes whether or not ≥1 event occurred 
within a particular timeframe. Some studies have considered hypoglycemia frequency as 
an ordinal outcome, with categories based on relative frequencies (e.g., once a month, one 
a week) or collapsing counts of hypoglycemia events into categories. For example, 
Donnelly et al. considered five categories of 0, 1, 2, 3, or ≥4 events over the past month8 
while Marrett et al. used bins of 1-2, 3-6, >6, >1 per month, >1 per week, or daily over the 
past 6 months89. As there is no standardized way of categorization, authors have used 
different categories and often provide limited or no justification for their decisions. At a 
population level, an inherent difference exists between never experiencing hypoglycemia 
and ≥1 event during a certain timeframe. However, it is difficult to define clinically-
meaningful categories of hypoglycemia frequency beyond a dichotomy of 0 and ≥1 events. 
The clinical relevance of the thresholds used to define each category hypoglycemia 
frequency requires more exploration.  
Though seemingly subtle, these different approaches to reporting and analyzing 
hypoglycemia occurrence impacts the interpretation of risk factor studies. They influence 
whether results have identified risk factors of never or ever experiencing hypoglycemia 
(when dichotomized), arbitrary bins of hypoglycemia frequency (when categorized), or 
risk factors associated with the incremental increase of NSH (when frequency is a count 
outcome). This heterogeneity in the data types used may also impede the comparability of 
studies and ease of clinical interpretation.  
   
20 
 
2.3.3 Analyzing hypoglycemia with regression models for count 
data 
In regression analyses, count data (i.e., number of hypoglycemia events) is conventionally 
modelled with a Poisson model. However, overdispersion (where variance exceeds mean 
number of events) in hypoglycemia data is common given the excess of zero counts and a 
wide range in non-zero counts due to the recurrent nature of the event. Excess zeros refer 
to the greater than expected counts of “no hypoglycemia events occurring” in a given 
count probability distribution). As a result, Poisson regression is often an inappropriate 
statistical model for hypoglycemia data as its assumption of equidispersion (i.e., variance 
being equivalent to mean number of events) is often violated. In fact, Poisson models have 
been shown to underestimate the number of zero counts and overestimate counts of one or 
two events when analyzing risk factors of severe hypoglycemia91.  
Negative binomial regression (NBR) is commonly used to model count outcomes of 
hypoglycemia frequency, along with the emerging use of zero-inflated negative binomial 
regression (ZINBR)88,92. The use of these models for hypoglycemia data, in the context of 
ascertaining risk factors91, has been supported by studies comparing model performance 
through simulations and secondary data analyses93,94. Negative binomial regression relaxes 
the assumption of equidispersion needed in a Poisson regression95. Although the 
underlying probability distribution of a NBR differs from a Poisson model, the 
exponentiated regression coefficients from a NBR are interpreted in the same manner (i.e., 
“after adjusting for covariates, a one unit change in independent variable x is associated 
with an expected n% increase/decrease in the incidence rate of y”).  
Zero-inflated negative binomial regression is an alternate model that accounts for 
overdispersion and excess zero counts (i.e., those that are greater than expected in a 
negative binomial distribution). This type of regression model attributes the occurrence of 
zero events to two sub-populations, one that contributes “structural zeros” (also known as 
“certain zeros”) and the other contributing “sampling zeros”96. To best illustrate the 
difference between these two types of zero, suppose a study investigating hypoglycemia 
comprised of patients with T2DM on any diabetes medications (both hypoglycemia-
inducible and hypoglycemia-uninducible types). Structural zeros would be attributed to 
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patients who would never experience any events of hypoglycemia as they are not at risk 
(i.e., those exclusively treated with medications that cannot induce hypoglycemia). 
Structural zeros are presumed to occur irrespective of sampling and thus, are the source of 
excess zeros in the data. On the other hand, “sampling zeros” would come from 
individuals who could experience events (i.e., those treated with hypoglycemia-inducible 
medications), but did not have any events when they were sampled into the study. This 
type of zero arises from sampling a population that has a probability (<100%) of 
experiencing no hypoglycemia events (as indicated in a negative binomial probability 
distribution) while structural zeros are attributed to a population that will always have zero 
events of hypoglycemia (i.e., a probability of 100%). The ZINBR is a two-component 
mixture model comprising of a logistic regression and a NBR which account for structural 
and sampling zeros, respectively. Thus, the overall interpretation of a ZINBR output 
requires two separate interpretations of the logistic model and NBR. The Vuong test can 
determine whether a ZINBR is as a good of a fit to the data as NBR, thus warranting its 
use97. 
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Chapter 3  
3 Methods 
The purpose of this chapter is: 
1) To describe the data source, study design, sampling strategy, and data collection 
used in this thesis (Section 3.1) 
2) To describe the outcome measure (InHypo-DM Patient Questionnaire) used in this 
thesis (Section 3.2)  
3) To detail the statistical analysis plan and sensitivity analyses (Section 3.3) 
3.1 Data source and study design  
The source of data for this thesis comes from the population-based, cross-sectional study 
titled “Understanding the Impact of Hypoglycemia on Diabetes Management: A Survey of 
Perspectives and Practices” (InHypo-DM), which is the largest investigation of 
hypoglycemia in Canada to date. The InHypo-DM Study sought to determine the real-
world epidemiology of hypoglycemia and factors influencing management behavior of 
hypoglycemia through the development, validation, and administration of three 
questionnaires, each targeting a different population: 1) individuals with Diabetes Mellitus 
at risk of hypoglycemia; 2) significant others of individuals with Diabetes Mellitus; and 3) 
healthcare providers. Given the scope of this thesis, any reference to the InHypo-DM 
Study henceforth will solely refer to the investigation of adults with Diabetes Mellitus 
at risk of hypoglycemia. Specifically, the InHypo-DM Study surveyed Canadian adults 
(≥18 years old) with Diabetes Mellitus (T1DM or T2DM) treated with insulin and/or 
secretagogues using the validated InHypo-DM Patient Questionnaire (InHypo-DMPQ). 
This thesis is a secondary analysis of data collected from study participants who had 
T2DM.    
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3.1.1 Sampling strategy and data collection 
Potential participants were recruited from an online i-Say panel created and maintained by 
Ipsos Interactive Services Ltd., a research polling firm in Canada. Ipsos Interactive 
Services Ltd. ensured a representative panel of high-quality respondents through various 
strategies that included multi-source recruitment (i.e., through a variety of online and 
offline methods), quota sampling, and quality control for panel membership and survey 
performance98. Prior to data collection in 2015, the i-Say panel consisted of 133,326 
Canadian members (Appendix B). Adult Canadians (≥18 years of age) in the i-Say panel 
were deemed representative of the general Canadian population based on comparisons to 
demographic results from the 2011 National Household Survey, which was part of the 
latest Canadian census available at the time of data collection (Appendix B). The 
inclusion criteria for the InHypo-DM Study were: 1) Canadian adults (≥18 years of age) 
with Diabetes Mellitus; 2) use of insulin and/or secretagogues; and 3) literacy in English 
and French. There were no exclusion criteria.  
Based on profile information previously collected by Ipsos Interactive Services Ltd., 2,706 
of the 133,326 i-Say panel members were ≥18 years of age and had self-reported Diabetes 
Mellitus (T1DM or T2DM). Potential participants were randomly selected (approximately 
20%) from the 2,706 members then approached in waves using a convenience sampling 
method to reach the pre-determined sample size of 552 respondents (with T1DM or 
T2DM). Individuals who were interested in participating completed an online pre-
screening question regarding the current type of diabetes medications used. Eligible 
participants who indicated use of insulin and/or secretagogues were invited into the study 
and asked to complete the InHypo-DMPQ, which was hosted on an online platform by 
Ipsos Interactive Services Ltd. Data collection occurred between November 20th to 
December 2nd, 2015. Respondents were offered i-Say points upon the completion of the 
InHypo-DMPQ by Ipsos Interactive Services Ltd. that could be redeemed for rewards. 
Ethics approval for this study was granted by the Western University Health Sciences 
Research Ethics Board (REB #105992, approved on December 16th 2014) prior to the 
commencement of this study (Appendix C). 
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The required sample size of 552 was estimated for the primary objective of the InHypo-
DM Study (i.e., to quantify the complex factors contributing to sub-optimal hypoglycemia 
management behaviour). In total, the InHypo-DM Study comprised of 94 respondents with 
T1DM and 458 respondents with T2DM. This thesis focused on respondents of the 
InHypo-DMPQ with T2DM. The sample used in this thesis was deemed to be 
representative of the general diabetes population in Canada based on distribution 
comparisons to results from the Canadian Community Health Survey and Survey on 
Living with Chronic Diseases (Appendix D).  
3.2 Outcome measure 
3.2.1 InHypo-DM Patient Questionnaire (InHypo-DMPQ)  
The InHypo-DMPQ was an 82-item questionnaire developed and validated for face and 
content validity in English. A professionally-translated version was also available in 
French. The InHypo-DMPQ was developed and validated using a mixed-method 
approach, which included: 1) a systematic review of existing questionnaires that evaluated 
determinants of glycemic management behaviour in adult (≥18 years old) with diabetes; 2) 
qualitative interviews of adults with diabetes; and 3) a validation study. The InHypo-
DMPQ comprised of three parts: the first assessed the behavioural determinants of 
hypoglycemia management, the second pertained to socio-demographic characteristics and 
diabetes-specific clinical characteristics, and the third assessed the retrospective frequency 
of symptomatic hypoglycemia. The items and response options for the second and third 
parts of the InHypo-DMPQ (i.e., socio-demographic/diabetes-specific characteristics and 
retrospective frequency of hypoglycemia) were informed by clinical/methodological 
expertise, questionnaires included in the systematic review, and feedback gleaned from 
participants of the validation study. The second and third parts of the InHypo-DMPQ are 
included in Appendix E as data collected from these sections were relevant to this thesis. 
The specific variables for socio-demographic/clinical characteristics used in this thesis are 
summarized in Table 6.  
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3.2.2 Non-severe hypoglycemia  
Non-severe hypoglycemia referred to an event of mild or moderate hypoglycemia that could 
be self-managed, as defined by the Diabetes Canada Clinical Practice Guidelines37 (Table 2). 
The definitions for any NSH, daytime NSH, and nocturnal NSH used in this thesis are 
provided in Table 5. Given that NSH is transient and can occur frequently, the potential for 
recall bias was considered during the development of the InHypo-DMPQ. The recall period of 
30 days for NSH was chosen in consultation with clinical expertise and the Food and Drug 
Administration document on patient-reported outcomes guidance73.  
Table 5. Definition for any, daytime, and nocturnal NSH 
Type  Definition 
Any NSH
  
A composite of daytime non-severe hypoglycemia and nocturnal 
non-severe hypoglycemia that occurred in the last 30 days.  
Daytime NSH A self-reported event of mild or moderate hypoglycemia that 
occurred during normal waking hours in the last 30 days and was 
self-managed (e.g., by drinking a glass of juice, eating something, 
or taking a sugar pill). Symptoms included sweatiness, hunger, 
anxiety, weakness, confusion, heart palpitations, difficulty 
speaking, and/or loss of concentration.  
Nocturnal NSH A self-reported event of mild or moderate hypoglycemia that 
occurred in the last 30 days when the respondent was sleeping or 
attempting to sleep and was self-managed (e.g., by drinking a 
glass of juice, eating something, or taking a sugar pill). Symptoms 
included sweatiness, hunger, anxiety, weakness, confusion, heart 
palpitations, difficulty speaking, and/or loss of concentration.  
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3.2.3 Age 
Age was reported in years as a continuous variable.   
3.2.4 Gender 
Gender was reported as a dichotomous variable: male or female.  
3.2.5 Annual household income 
Annual household income was reported as a categorical variable in the following income 
brackets (in Canadian Dollars): “less than $ 30,000”, “$ 30,000 to $ 50,000”, “$ 51,000 to 
$ 75,000”, or “greater than $ 75,000”. 
3.2.6 Education level 
Highest level of education was treated as a categorical variable of: “elementary or high 
school”, “technical school, college, or CEGEP”, “university or graduate or professional 
school”. CEGEP (a French acronym for Collège d'enseignement général et professionnel) 
is a program unique to the Canadian province of Quebec that provides “general and 
vocational college” for students intending to pursue university or for students pursuing 
studies in skilled trades99.   
3.2.7 Current living arrangements 
Current living arrangements was treated as dichotomous: “living alone” and “not living 
alone. Those who were not living alone included those living with a spouse/significant 
other, family member(s), or a roommate/boarder. The dichotomization of this variable was 
informed by previous studies on risk factors for NSH42,85,86.  
3.2.8 Employment status 
Employment status was treated as dichotomous: “working full-time or part-time or 
seasonal” or “other” (i.e., unemployed, retired, not working due to a disability, a student 
who is not working full-time or part-time). The dichotomization of this variable was 
informed by previous studies on risk factors for NSH42,85,86.   
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3.2.9 Drug coverage 
Drug coverage was treated as a dichotomous variable: whether or not respondents had 
drug coverage. Drug coverage included provincial drug benefits and/or third-party benefits 
(e.g., private or through work). 
3.2.10 Diabetes duration 
Duration of diabetes was reported in years since diagnosis as a continuous variable.  
3.2.11 Hemoglobin A1c 
Most recent level of hemoglobin A1c (HbA1c) was reported in % as a continuous variable.    
3.2.12 Comorbidity status 
Presence of health conditions which may impede one’s self-management of hypoglycemia 
was reported as a dichotomous variable (i.e., yes or no) through the questionnaire item, 
“Do you have other health conditions that get in the way of your management of your 
hypoglycemia?”.  
3.2.13 Type of diabetes medication  
Type of diabetes medications currently used was reported as a categorical variable: 
secretagogues only, insulin only, or combination therapy (i.e., secretagogues and insulin). 
Secretagogues included glinides (i.e., nateglinide, repaglinide) and sulfonylureas (i.e., 
gliclazide, glyburide, glimepiride, chlorpropamide, tolbutamide).  
3.2.14 Main healthcare provider 
Main healthcare provider was treated as a dichotomous variable: whether or not 
respondents indicated that they received the majority of their diabetes care from specialist 
(i.e., endocrinologist or internist). This dichotomization was based on previous literature 
on risk factors of NSH86 and the rationale that the need for specialist care reflects a 
medically-complex individual with diabetes. 
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Table 6. Socio-demographic and clinical risk indicators of interest  
Socio-demographic Risk 
Indicator 
Description of variable 
Age  Continuous (in years) 
Gender  Dichotomous: 
- Male 
- Female  
Annual household income 
 
Categorical: 
- <$ 30,000 
- $ 30,000 to $ 50,000 
- $ 51,000 to $ 75,000 
- >$ 75,000 
Education level 
 
Categorical:  
- Elementary school or High school 
- CEGEP/Technical school or College 
- University or Graduate/Professional school 
Current living arrangement Dichotomous: 
- Living alone  
- Not living alone 
Employment status 
 
Dichotomous:  
- Working (i.e., full-time, part-time, or seasonal)  
- Other (i.e., unemployed or stay-at-home parent or 
student or retired or disabled) 
Drug coverage 
 
Categorical:  
- None 
- Government-funded (i.e., provincial drug plan or 
veteran affairs)  
- Third-party private or other  
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Clinical Risk Indicator Description of variable 
Duration of Diabetes Continuous (in years) 
Most recent HbA1c Continuous (in %) 
Comorbidity status  Dichotomous: 
- Yes  
- No 
Medication Type  Categorical:  
- Secretagogues (i.e., sulfonylurea, glinide) alone 
- Insulin alone  
- Combination (insulin and secretagogues)  
Main Healthcare Provider  Dichotomous:  
- Involves a specialist 
- Does not involve a specialist 
3.2.15 Rationale for excluding items collected in the InHypo-DMPQ 
as potential risk indicators in this thesis 
There were six items collected in the InHypo-DMPQ that were not considered as potential 
risk indicators in this thesis: use of continuous glucose monitoring (CGM) device, number 
of insulin injections, shiftwork status, current occupation (collected as an open-ended 
question of “if you are employed, what is your current occupation?”), payer for the 
majority of glucose testing strips, and payer for the majority of insulin and/or oral glucose-
lowering therapies. Given the high cost of CGM devices, only very selective sub-
populations of individuals with diabetes have access to such technology through public 
funding, which also vary by province/territory, or through private funding from a limited 
number of insurance companies in Canada100. Thus, use of CGM device was not 
considered in this thesis. Employment status was included in lieu of shiftwork status and 
current occupation to prevent multicollinearity as these two variables were conditional on 
being employed. Furthermore, employment status was hypothesized to broadly encompass 
both variables in reflecting the respondents’ workplace environment and the nature of their 
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job as a latent risk indicator for hypoglycemia. The payer for the majority of glucose test 
strips and the payer for the majority of insulin and/or oral glucose-lowering therapies were 
not included in this thesis as it was hypothesized that these two variables would be 
indicated by the included variable of drug coverage. Although insulin regimens may be 
inferred from the number of insulin injections reported, the relationship between specific 
insulin regimens and occurrence of hypoglycemia was thought to be most appropriately 
addressed in different, more focused research question. Thus, number of insulin injections 
was not considered in this thesis; rather, the broad use of insulin, regardless of type of 
regimen, was accounted for in variable of medication type.  
3.3 Statistical analysis  
Univariable analyses were conducted to describe the distribution of potential risk 
indicators and the incidence of NSH among the study sample. Continuous variables were 
reported as mean and standard deviations or for non-parametric variables, as median and 
interquartile range (IQR). Categorical variables were reported as frequency and 
percentage. The incidence proportion (% of respondents who experienced ≥ 1 NSH event 
within the past 30 days), incidence rate for the past 30 days (number of NSH events per 30 
person-days), annualized incidence rate (number of NSH events per person-year) of NSH 
and their associated 95% confidence intervals were reported. Little's MCAR (missing 
completely at random) test101 was computed by the mcartest command in Stata102 to 
confirm that missing data were indeed MCAR, thus suggesting that listwise deletion of 
participants with missing data would not introduce bias.  
3.3.1 Multivariable analysis for objectives 1 – 3  
For Objectives 1 to 3, negative binomial regression (NBR) using backward selection 
(p<0.05) was used to identify independent risk indicators for any NSH (Objective 1), 
daytime NSH (Objective 2), and nocturnal NSH (Objective 3). Three separate models were 
built, one for each outcome. Daytime NSH and nocturnal NSH were modelled as separate 
outcomes on the basis that they reflect different clinical experiences and consequences. It 
is harder to gain awareness of nocturnal NSH as individuals are asleep, thus prolonging the 
duration and delaying the treatment of such events40. Furthermore in comparison to 
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daytime NSH, nocturnal NSH imparts a significantly greater psychological burden86 and 
requires a longer recovery time, resulting in loss of work productivity and 
absenteeism58,67,103,104.  
Given the exploratory nature of these analyses, automated variable selection procedures, 
such as backward and forward section, were considered. Backward variable selection was 
used as two variables (or more) that are equally explanatory of the outcome would not 
both be discarded from the final model, but either one or the other could be removed105. A 
stopping criterion of p<0.05 was used as potential candidates for socio-demographic risk 
indicators (age, gender, annual household income, education level, living arrangements, 
employment status, drug coverage) and clinical risk indicators (duration of T2DM, most 
recent HbA1c, comorbidity status, medication type, main healthcare provider) were pre-
selected based on: 1) clinical plausibility; 2) literature41,42,68,71,85,87 and clinical guidelines72 
detailing current evidence on risk indicators for hypoglycemia, and 3) methodological 
considerations to whether multiple variables were thought to represent the same latent 
construct. Variance inflation factors confirmed the absence of multicollinearity among the 
potential risk indicators. Model fit was assessed using the deviance statistic to confirm the 
appropriate use of NBR in accommodating for over-dispersion. Although the deviance 
statistic suggested slight underdispersion in the model constructed for nocturnal NSH, 
NBR was still deemed the most suitable count model for nocturnal NSH for two reasons: 
1) the Akaike Information Criterion value was smaller for a NBR compared to a Poisson 
regression, suggesting that a NBR was a better fit than a Poisson regression; and 2) a zero-
inflated negative binomial regression model could not be constructed as it failed to 
converge. A residual plot of standardized deviance residuals compared to the predicted 
values for NSH frequency was used to identify potential outliers (i.e., standardized 
deviance residuals ≥2 or ≤-2)106. 
3.3.2 Multivariable analysis for objective 4 
For Objective 4a, the frequency of any NSH events occurring within the last 30 days were 
binned into four categories: “0”, “1”, “2 to 4”, or “greater than 4” events. The first 
category of “0” NSH events was chosen based on the rationale that there is a clinically-
meaningful difference between experiencing no events compared to at least one event. 
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This rationale was also supported by a study which determined that a minimum of ten 
NSH events per year would be clinically important based on health utilities elicited from 
Canadians adults with diabetes107. As our outcome of interest was captured within a 30-
day timeframe (which is synonymous with a 1-month timeframe), the conservative 
equivalent of a minimum of ten events per year on a 30-day scale would be a minimum of 
one NSH event (
10 𝑁𝑆𝐻 𝑒𝑣𝑒𝑛𝑡𝑠
12 𝑚𝑜𝑛𝑡ℎ𝑠
= 0.83
𝑒𝑣𝑒𝑛𝑡𝑠
𝑚𝑜𝑛𝑡ℎ
 rounded to 1
𝑒𝑣𝑒𝑛𝑡
𝑚𝑜𝑛𝑡ℎ
 as NSH event frequency 
must be an integer). The definition for the remaining categories were informed by previous 
studies which reported categories of relative frequencies (e.g., once a week, once a 
month)2,90. The remaining categories of “1”, “2 to 4”, and “greater than four” events were 
selected as they are conservative equivalents of events occurring “once a month”, “at least 
once biweekly but less than once a week”, and “at least once a week”, respectively, on a 
30-day scale. A subsequent look at the data revealed that the distribution of our data 
aligned with the thresholds used for these categories; when counts of zero events were 
excluded, the 25th percentile, median, and 75th percentile of our data on NSH frequency 
was 1, 2, and 4, respectively.    
For Objective 4b, a proportional odds (PO) model with backwards variable selection 
(p<0.05) identified independent risk indicators for any NSH, treated as an ordinal outcome 
using the categories described above (Objective 4a). The assumption for proportional odds 
were confirmed by the Score Test in univariable analyses and the final PO model. As 
recommended by Hosmer & Lemeshow (2000)108, model diagnostics were assessed for the 
three separate logistic regression models defined by each of the three cutpoints for ordinal 
outcome of any NSH used in the PO model. These three logistic regressions modelled: 1) 
the binary outcome of ‘0’ vs. ‘≥1’ events; 2) the binary outcome of ‘0 and 1’ vs. ‘2 to 4 
and >4’ events; and 3) the binary outcome of ‘0 and 1 and 2 to 4’ vs. ‘>4’ events. 
Residual analysis (i.e., examining an index plot of standardized pearson residuals) was 
conducted to identify potential outliers. A plot of DFBETA values against estimated 
outcome probabilities was examined to identify influential observations. The Hosmer-
Lemeshow test was used to confirm model adequacy.  
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All data analyses were conducted using SAS 9.4 (SAS Institute, Inc., Cary, North 
Carolina) and Stata 13.0 (StataCorp, College Station, Texas). All statistical tests were two-
sided with a significance level of α=0.05.  
3.3.3 Sensitivity analyses 
Two sensitivity analyses were conducted:  
1) For Objectives 1-3, potential outliers identified in the residual analyses for the 
original three NBR models were excluded and multivariable analyses were re-
conducted. This sensitivity analysis was not conducted for Objective 4b as model 
diagnostics examined the three underlying binomial models within the PO model 
rather than the overall PO model.  
2) For Objective 4b, the assumption for PO was evaluated based on visual inspection 
of the empirical logit plots for each of the potential risk indicators instead of the 
Score Test. The rationale for this sensitivity analysis was based on the suggestion 
that the Score Test may be anti-conservative (i.e., lacks power to detect moderate 
violations of the PO assumption)109. Based on empirical logit plots generated from 
the Empirical Logit Plot SAS macro110, five risk indicators (i.e., duration of 
disease, annual household income, education level, HbA1c levels and medication 
type) were deemed to have mildly violated the PO assumption in univariable 
analysis (Appendix F). Thus, a partial proportional odds (PPO) model with 
backwards selection (p<0.05) was conducted where these five risk indicators were 
considered in its ‘unequal slopes’ form (i.e., with effect measures of PPO ratio), in 
additional to all twelve candidate risk indicators in their ‘equal slopes’ form (i.e., 
with effect measures of PO ratio) in SAS.   
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Chapter 4  
4 Results 
The purpose of this chapter is:  
1) To describe the flow of sample participation and their characteristics (Section 4.1) 
2) To describe the incidence of NSH and the distribution of NSH data (Section 4.2) 
3) To report the findings regarding risk indicators for the frequency of any NSH 
(Objective 1), daytime NSH (Objective 2), nocturnal NSH (Objective 3) (Section 4.3) 
4) To report the findings regarding risk indicators for the frequency of any NSH 
treated as an ordinal outcome (Objective 4) (Section 4.4) 
5) To summarize the findings of the four objectives in this thesis (Section 4.5) 
4.1 Participants and their characteristics 
The recruitment, participation of the study sample, and inclusion of respondents in 
this thesis are summarized in Figure 1. Among the 552 individuals with diabetes who 
completed the InHypo-DMPQ, 94 and 458 individuals had T1DM and T2DM, 
respectively45. Of the 458 respondents with T2DM, two individuals were excluded as they 
provided erroneous responses (i.e., duration of diabetes exceeded age). Only 24 of the 
remaining 456 (5.26%) respondents had missing data for the variables of interest; twenty 
individuals had missing data for HbA1c, three individuals had missing data for annual 
household income, and one individual had missing data for daytime NSH and HbA1c. 
Complete case analysis was used because of such a low percentage of missing data and 
also Little's MCAR test did not suggest strong evidence against the assumption of data 
being missing completely at random (χ2=36.8277, df=35, p=0.38).   
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Figure 1. Flow diagram outlining the sample recruitment and participation for the InHypo-
DM study and inclusion of respondents in this thesis.  
The socio-demographic and clinical characteristics of the sample are summarized in 
Table 7. Among the 432 individuals with T2DM, 189 (43.8%) were female and 243 
(56.2%) were male. These individuals had a mean age of 53.1 years (standard deviation: 
14.7) and mean duration of diabetes of 11.6 years (standard deviation: 7.6 years). The 
most common type of diabetes medication used was secretagogues alone (n=204, 47.2%), 
followed by insulin alone (n=149, 34.5%), and a combination therapy of insulin and 
secretagogues (n=79, 18.3%). Participants had a median HbA1c of 7.1% and an 
interquartile range of 2.5%, ranging from 6.25% to 8.75% (mean = 9.1%, standard 
deviation = 5.9%). Two hundred and six (47.7%), 120 (27.8%), and 106 (24.5%) 
individuals had a HbA1c level of ≤7%, >7% to <9%, and ≥9%, respectively.  
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Table 7. Socio-demographic and clinical characteristics of respondents with T2DM 
Variable 
n=432 
Socio-demographic Characteristics 
Age (years) – mean ± SD 53.1 years ±14.7 
Female – no. (%) 189 (43.8%) 
Annual Household Income (Canadian Dollars) – no. (%)  
     < $30,000 121 (28.0%) 
     $30,000 to $50,000 89 (20.6%) 
     $51,000 to $75,000 90 (20.8%) 
     > $75,000 132 (30.6%) 
Highest Level of Education – no. (%)  
     Elementary or high school 119 (27.6%) 
     Technical school or college or CEGEP 157 (36.3%) 
     University or graduate/professional school 156 (36.1%) 
Living Alone – no. (%) 295 (68.3%) 
Employment Status – no. (%)  
     Working full-time or part-time or seasonal 213 (49.3%) 
Other (i.e., unemployed, retired, disability, or unemployed student) 219 (50.7%) 
Has drug coverage (i.e., provincial drug benefits and/or third-party 
benefits) 
393 (91.0%) 
Clinical characteristics  
Duration of diabetes (years) – mean ± SD 11.6 years ± 7.6 
HbA1c (%) – median (IQR) 7.1% (2.5) 
Presence of comorbidity – no. (%) 103 (23.8%) 
Current type of diabetes medication(s) – no. (%)  
      Secretagogues alone  204 (47.2%) 
      Insulin alone 149 (34.5%) 
      Combination (i.e., Insulin and Secretagogues) 79 (18.3%) 
Has a specialist as a main HCP – no. (%) 65 (15.1%) 
Abbreviations: CEGEP: College d’enseignment general et professionnel; HbA1c: 
Hemoglobin A1C; HCP: healthcare provider; IQR: Interquartile range; SD: standard 
deviation 
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4.2 Incidence and distribution of NSH 
The crude incidence estimates for NSH are summarized in Table 8. Among this sample of 
432 individuals, 233 (53.9%), 221 (51.2%), and 131 (30.3%) individuals had one or more 
event(s) of any, daytime, and nocturnal NSH occurring in the past 30 days, respectively. A 
total of 976 events of any NSH occurred within the last 30 days, of which 592 were events 
of daytime NSH and 384 were events of nocturnal NSH. Thus, the incidence rate of any, 
daytime, and nocturnal NSH within the last 30 days was 2.3 (95% CI: 2.1 to 2.4), 1.4 (95% 
CI: 1.3 to 1.5), and 0.9 (95% CI: 0.9 to 0.10) events per 30 person-days, respectively. The 
annualized incidence rate of any, daytime, and nocturnal NSH was 27.5 (95% CI: 25.8 to 
29.3), 16.7 (95% CI: 15.4 to 18.1), 10.8 (95% CI: 9.8 to 12.0) events per person-year, 
respectively. 
Overdispersion of hypoglycemia data is clearly indicated by comparing the mean NSH 
event frequency to the variance of NSH event frequency. The mean and variance for the 
number of any NSH events were 2.3 and 26.5, respectively. The mean and variance for the 
number of daytime NSH events were 1.4 and 7.5, respectively. The mean and variance for 
the number of nocturnal NSH events were 0.9 and 9.3, respectively.  
Table 8. Crude estimates of the incidence proportion, incidence rate, and annualized 
incidence rate for NSH among the study sample (n=432) 
  Any NSH Daytime NSH Nocturnal NSH 
Incidence Proportion, % of 
individuals who had ≥1 event within 
the last 30 days (95% CI) 
53.9% 
(49.2% to 58.6%) 
51.2% 
(46.4% to 55.9%) 
30.3% 
(26.0% to 34.7%) 
Incidence Rate, no. of events per 30 
person-days (95% CI) 
2.3 
(2.1 to 2.4) 
1.4 
(1.3 to 1.5) 
0.9 
(0.8 to 1.0) 
Annualized Incidence Rate, no. of 
events per person-year (95% CI) 
27.5 
(25.8 to 29.3) 
16.7 
(15.4 to 18.1) 
10.8 
(9.8 to 12.0) 
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4.3 Risk indicators for the frequency of NSH  
4.3.1 Any NSH (Objective 1) 
Based on the final negative binomial regression (NBR) model, the significant risk indicators 
independently associated with a higher frequency of any NSH were: younger age, lower 
annual household income, being employed, having a longer duration of diabetes, higher 
HbA1c, and presence of comorbidities. The crude and adjusted estimates of association for 
each risk indicator are shown in Table 9. The ratio of deviance to degrees of freedom 
(deviance/df) for the final NBR model was 1.01, indicating the model fit the data well.  
4.3.2 Daytime NSH (Objective 2) 
Based on the final NBR model, the significant risk indicators independently associated with a 
higher frequency of daytime NSH were: younger age, lower annual household income, being 
employed, higher HbA1c, type of diabetes medications used, and presence of comorbidities. 
The crude and adjusted estimates of association for each risk indicator are shown in Table 10. 
In comparison to those who were using secretagogues alone, the use of insulin alone and the 
use of combination therapy (insulin and secretagogues) were independently associated with a 
42% (95% CI: 3% to 97%) and 80% (95% CI: 26% to 158%) increase in the expected 
incidence rate of daytime NSH, respectively, adjusting for the aforementioned variables in the 
model. The use of combination therapy in comparison to insulin alone did not achieve 
statistical significance, although it trended towards an association with increased rates of 
daytime NSH. The deviance/df statistic for the final NBR model was 0.97, suggesting the 
model fits the data well.   
4.3.3 Nocturnal NSH (Objective 3) 
Based on the final NBR model, the significant risk indicators independently associated with a 
higher frequency of nocturnal NSH were: younger age, lower annual household income, 
higher HbA1c, and presence of comorbidities. The crude and adjusted estimates of association 
for each risk indicator are shown in Table 11. The deviance/df statistic for the final NBR 
model was 0.72, suggesting a slightly overfit of the data. However as detailed in Chapter 
3.3.1, the NBR model was deemed the best fit for the data.
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Table 9. Incidence rate ratios (IRR) for any NSH based on univariable analyses and the final multivariable NBR model 
  Univariable Analysis Multivariable Analysis†  
Risk Indicators 
Crude 
IRR 
95% CI p-value 
Adjusted 
IRR 
95% CI p-value 
Age (per 1-year increase) 0.97 0.96 0.98 <0.001 0.97 0.96 0.98 <0.001 
Gender (Female vs. Male*) 0.96 0.69 1.33 0.78 - - - - 
Annual Household Income (CAD)   
  
<0.001   
  
<0.001 
   $30,000 to 50,000 vs. <$30,000* 0.68 0.44 1.07 
 
0.57 0.38 0.85  
   $51,000 to 75,000 vs. <$30,000* 0.53 0.34 0.83 0.37 0.24 0.58 
   >$75,000 vs. <$30,000* 0.36 0.24 0.54 0.29 0.19 0.44 
Education Level       0.22       -  
   CEGEP/Technical School/College vs. Elementary/High School* 0.72 0.48 1.09 
 
- - - - 
   University/Graduate/Professional School vs. Elementary/High School* 0.74 0.49 1.11 - - - - 
Living Alone (vs. Other*) 0.96 0.68 1.36 0.82 - - - - 
Employment Status (Working vs. Other*) 1.46 1.06 2.02 0.02 1.45 1.01 2.09 0.04 
Drug Coverage (Yes vs. No*) 0.62 0.36 1.08 0.09 - - - - 
T2DM Duration (per 1-year increase) 1.01 0.99 1.03 0.37 1.03 1.01 1.05 0.006 
HbA1c (per 1% increase) 1.07 1.04 1.09 <0.001 1.03 1.01 1.06 0.006 
Medication Type       0.03    - 
   Insulin alone vs. Secretagogues alone* 0.76 0.53 1.09 
 
- - - - 
   Combination (i.e., Insulin and Secretagogues) vs. Secretagogues alone* 1.41 0.91 2.18 - - - - 
   Combination (i.e., Insulin and Secretagogues) vs. Insulin alone* 1.86 1.18 2.96  - - - - 
Presence of Comorbidities (vs. Absence*) 2.48 1.74 3.55 <0.001 2.09 1.53 2.86 <0.001 
Main Healthcare Provider (Specialist vs. No Specialist*) 0.72 0.46 1.15 0.17 - - - - 
*Reference group 
†All risk indicators selected for inclusion into the final multivariable model through backward selection are listed  
  
Abbreviations: CAD: Canadian Dollar; CI: Confidence Interval, HbA1c: Hemoglobin A1c; IRR: Incidence Rate Ratio; vs.: versus 
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Table 10. Incidence rate ratios (IRR) for daytime NSH based on univariable analyses and the final multivariable NBR model 
  Univariable Analysis Multivariable Analysis†  
Risk Indicators 
Crude 
IRR 
95% CI p-value 
Adjusted 
IRR 
95% CI p-value 
Age (per 1-year increase) 0.98 0.97 0.99 <0.001 0.98 0.97 0.99 <0.001 
Gender (Female vs. Male*) 0.96 0.71 1.30 0.79 - - - - 
Annual Household Income (CAD)   
  
<0.001   
  
<0.001 
   $30,000 to 50,000 vs. <$30,000* 0.73 0.48 1.10 
 
0.58 0.39 0.86 
 
   $51,000 to 75,000 vs. <$30,000* 0.63 0.41 0.95 
 
0.41 0.27 0.63 
   >$75,000 vs. <$30,000* 0.45 0.30 0.66 
 
0.35 0.23 0.52 
Education Level       0.53       - 
   CEGEP/Technical School/College vs. Elementary/High School* 0.89 0.61 1.30 
 
- - - - 
   University/Graduate/Professional School vs. Elementary/High School* 0.80 0.55 1.18 - - - - 
Living Alone (vs. Other*) 0.99 0.72 1.37 0.95 - - - - 
Employment Status (Working vs. Other*) 1.38 1.02 1.86 0.04 1.43 1.002 2.03 0.049 
Drug Coverage (Yes vs. No*) 0.67 0.41 1.11 0.12 - - - - 
T2DM Duration (per 1-year increase) 1.01 0.99 1.03 0.49 - - - - 
HbA1c (per 1% increase) 1.05 1.03 1.08 <0.001 1.03 1.00 1.05 0.03 
Medication Type        0.01       0.003 
  Insulin alone vs. Secretagogues alone* 0.99 0.71 1.39 
 
1.42 1.03 1.97 
 
  Combination (i.e., Insulin and Secretagogues) vs. Secretagogues alone* 1.71 1.15 2.54 1.80 1.26 2.58 
  Combination (i.e., Insulin and Secretagogues) vs. Insulin alone* 1.72 1.13 2.61  1.26 0.86 1.86  
Presence of Comorbidities (vs. Absence*) 2.45 1.78 3.38 <0.001 2.16 1.60 2.92 <0.001 
Main Healthcare Provider (Specialist vs. No Specialist*) 0.86 0.56 1.31 0.48 - - - - 
*Reference group 
†All risk indicators selected for inclusion into the final multivariable model through backward selection are listed 
   
Abbreviations: CAD: Canadian Dollar; CI: Confidence Interval, HbA1c: Hemoglobin A1c; IRR: Incidence Rate Ratio; vs.: versus 
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Table 11. Incidence rate ratios (IRR) for nocturnal NSH based on univariable analyses and the final multivariable NBR model. 
  Univariable Analysis Multivariable Analysis†  
Risk Indicators 
Crude 
IRR 
95% CI p-value 
Adjusted 
IRR 
95% CI p-value 
Age (per 1-year increase) 0.95 0.94 0.96 <0.001 0.95 0.94 0.96 <0.001 
Gender (Female vs. Male*) 0.95 0.60 1.51 0.82 - - - - 
Annual Household Income (CAD)   
  
<0.001   
  
<0.001 
   $30,000 to 50,000 vs. <$30,000* 0.63 0.34 1.17 
 
0.58 0.34 0.98 
 
   $51,000 to 75,000 vs. <$30,000* 0.40 0.21 0.75 0.36 0.20 0.63 
   >$75,000 vs. <$30,000* 0.25 0.14 0.45 0.23 0.14 0.40 
Education Level       0.07       - 
   CEGEP/Technical School/College vs. Elementary/High School* 0.52 0.29 0.92  - - - 
 
   University/Graduate/Professional School vs. Elementary/High School* 0.66 0.37 1.16 - - - 
 
Living Alone (vs. Other*) 0.92 0.56 1.50 0.73 - - - - 
Employment Status (Working vs. Other*) 1.60 1.02 2.53 0.04 - - - - 
Drug Coverage (Yes vs. No*) 0.56 0.26 1.20 0.14 - - - - 
T2DM Duration (per 1-year increase) 1.01 0.98 1.04 0.35 - - - - 
HbA1c (per 1% increase) 1.08 1.05 1.12 <0.001 1.04 1.01 1.07 0.004 
Medication Type    0.02    - 
   Insulin alone vs. Secretagogues alone* 0.49 0.29 0.82 
 
- - - 
 
  Combination (i.e., Insulin and Secretagogues) vs. Secretagogues alone* 1.07 0.58 1.96 - - - 
 
  Combination (i.e., Insulin and Secretagogues) vs. Insulin alone* 2.20 1.14 4.25  - - -  
Presence of Comorbidities (vs. Absence*) 2.54 1.53 4.20 <0.001 1.73 1.13 2.64 0.01 
Main Healthcare Provider (Specialist vs. No Specialist*) 0.53 0.27 1.04 0.07 - - - - 
*Reference group 
†All risk indicators selected for inclusion into the final multivariable model through backward selection are listed 
 
Abbreviations: CAD: Canadian Dollar; CI: Confidence Interval, HbA1c: Hemoglobin A1c; IRR: Incidence Rate Ratio; vs.: versus 
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4.4 Risk indicators for the categorical frequency of any NSH 
(Objective 4) 
The number and proportion of individuals included in each category of NSH event frequency are 
detailed in Table 12. These categories were defined in Chapter 3.3.2 and used as the outcome 
variable in the proportional odds (PO) model. Based on the final PO model, the significant risk 
indicators independently associated with a higher frequency of any NSH were: younger age, 
lower annual household income, being employed, higher HbA1c levels, type of diabetes 
medication used and presence of comorbidities. The crude and adjusted estimates of association 
for each risk indicator are shown in Table 13. The assumption for proportional odds were met in 
the final model based on the Score Test (χ2=27.82, df=18, p=0.06).    
 
Table 12. Proportion of individuals in each category of NSH event frequency 
Category  No. of individuals (%*) 
0 events in the last 30 days 
(none) 
199 (46.1%) 
1 event in the last 30 days  
(once a month) 
62 (14.4%) 
2-4 events in the last 30 days  
(at least once biweekly but 
less than once a week)  
117 (27.1%) 
>4 events in the last 30 days  
(at least once a week) 
54 (12.5%) 
Note: Sum of percentages exceed 100% due to rounding 
   
43 
 
Table 13. Odds ratios (ORProp) for any NSH (categorical outcome) based on univariable analyses and the final multivariable proportional odds model.  
 Univariable Analysis  Multivariable Analysis
†  
Risk Indicators 
Crude 
ORProp 
95% CI p-value 
Adjusted  
ORProp 
95% CI p-value 
Age (per 1-year increase) 0.96 0.95 0.97 <0.001 0.97 0.95 0.98 <0.001 
Gender (Female vs. Male*) 1.23 0.86 1.75 0.25 - - - - 
Annual Household Income (CAD)       0.07       0.004 
   $30,000 to 50,000 vs. <$30,000* 1.18 0.71 1.94 
 
1.01 0.59 1.71 
 
   $51,000 to 75,000 vs. <$30,000* 0.94 0.57 1.56 0.61 0.35 1.06 
   >$75,000 vs. <$30,000* 0.63 0.40 1.00 0.43 0.25 0.73 
Education Level   
  
0.87 - - - - 
   CEGEP/Technical School/College vs. Elementary/High School* 1.04 0.67 1.63   - - - - 
   University/Graduate/Professional School vs. Elementary/High School* 1.12 0.72 1.76   - - - - 
Living Alone (vs. Other*) 1.27 0.87 1.85 0.21 - - - - 
Work (Employed vs. Other*) 2.08 1.46 2.97 <0.001 1.64 1.02 2.61 0.04 
Drug Coverage (Yes vs. No*) 0.87 0.48 1.58 0.65 - - - - 
T2DM Duration (per 1-year increase) 0.98 0.95 1.00 0.06 - - - - 
HbA1c (per 1% increase) 1.08 1.05 1.11 <0.001 1.05 1.02 1.08 0.002 
Medication Type   
  
0.02   
  
0.02 
   Insulin alone vs. Secretagogues Alone* 1.32 0.90 1.96 
 
1.47 0.98 2.23  
   Combination (i.e., Insulin and Secretagogues) vs. Secretagogues Alone* 1.99 1.23 3.22 1.98 1.20 3.27 
   Combination (i.e., Insulin and Secretagogues) vs. Insulin Alone* 1.50 0.91 2.47  1.34 0.80 2.26  
Presence of Comorbidities (vs. Absence*) 2.58 1.70 3.93 <0.001 2.43 1.59 3.72 <0.001 
Main Healthcare Provider (Specialist vs. No Specialist*) 1.21 0.76 1.92 0.43 - - - - 
          Score Test χ2,18 =27.82 p=0.07 
*Reference Group 
†All risk indicators selected for inclusion into the final multivariable model through backward selection are listed 
Abbreviations: CAD: Canadian Dollar; HbA1c: Hemoglobin A1c; ORProp: Proportional Odds Ratio; vs.: versus 
Note: The PO model expresses the log odds of being in a frequency category or higher. For example, the adjusted ORProp for “Work” = 1.64 
is interpreted as a 64% increase in the expected odds of having “1 event or 2-4 events or >4 events” (i.e., odds = 
P(𝑌 = second or third or fourth outcome category)
P(𝑌 = first category) 
; where Y=predicted NSH frequency category) among individuals who were employed compared 
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to “other”, adjusting for all covariates. This magnitude of increase in the expected odds is consistent for the odds of having “2-4 events or >4 
events” (i.e., odds = 
P(𝑌 = third or fourth outcome category)
P(𝑌 = first or second outcome category) 
) and the odds of having “>4 events” (i.e., odds 
=
P(𝑌 = fourth outcome category)
P(𝑌 = first or second or third outcome category) 
).  
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4.4.1 Sensitivity Analysis #1 – removing outliers 
Four potential outliers were identified in the final model for any NSH (Objective 1). 
When these four observations were dropped, the significant risk indicators for any NSH 
included type of diabetes medication used in addition to the six risk indicators identified 
in the original final model (Table 9). The crude and adjusted estimates of association for 
each risk indicator in this revised model with outliers removed are shown in Appendix 
G. Six outliers were identified in the final model for daytime NSH (Objective 2). When 
these six observations were dropped, the significant risk indicators identified for daytime 
NSH remained consistent with results identified in the original final model (Table 10). 
The crude and adjusted estimates of association for each risk indicator in this revised 
model with outliers removed are shown in Appendix H. Five outliers were identified in 
the final model for nocturnal NSH (Objective 3). When these five observations were 
removed, the significant risk indicators for nocturnal NSH included duration of diabetes 
in addition to the four risk indicators identified in the original final model (Table 11). 
The crude and adjusted estimates of association for each risk indicator in this revised 
model with outliers removed are shown in Appendix I.  
4.4.2 Sensitivity Analysis #2 – partial proportional odds model  
Based on the final partial proportional odds (PPO) model, the significant risk indicators 
independently associated with a higher frequency of any NSH were: younger age, lower 
annual household income, being employed, higher HbA1c levels, type of diabetes 
medication used and presence of comorbidities. HbA1c level was the only risk indicator 
included in the final model with a different effect measure for each outcome category. 
Results from the final multivariable PPO model are shown in Appendix J. These risk 
indicators were identical to the risk indicators identified in the PO model for Objective 4 
4.5 Summary of results 
The independent risk indicators for any NSH (Objective 1), daytime NSH (Objective 2), 
nocturnal NSH (Objective 3), and any NSH treated as an ordinal outcome (Objective 4) 
are summarized in Table 14 with the magnitude of effects further depicted in Figure 2.
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Table 14. Summary of multivariable results for all four objectives 
Risk Indicators 
Any NSH  
(Objective 1) 
Daytime NSH 
(Objective 2) 
Nocturnal NSH 
(Objective 3) 
Any NSH  
(Objective 4) 
Age (per 1-year increase)    
Gender (Female vs. Male*) - - - - 
Annual Household Income (CAD)    
   $30,000 to 50,000 vs. <$30,000*    †
   $51,000 to 75,000 vs. <$30,000*    
   >$75,000 vs. <$30,000*    
Education Level     
   CEGEP/Technical School/College vs. Elementary/High School* - - - - 
   University/Graduate/Professional School vs. Elementary/High School* - - - - 
Living Alone (vs. Other*) - - - - 
Work (Employed vs. Other*)   - 
Drug Coverage (Yes vs. No*)     
T2DM Duration (per 1-year increase)  - - - 
HbA1c Level (per 1% increase)    
Medication Type    
   Insulin alone vs. Secretagogues Alone* -  - 
   Combination (i.e., Insulin and Secretagogues) vs. Secretagogues Alone* -  - 
   Combination (i.e., Insulin and Secretagogues) vs. Insulin Alone* -  - 
Presence of Comorbidity (vs. Absence*)    
Main Healthcare Provider (Specialist vs. No Specialist*) - - - - 
*Reference Group     
Abbreviations: CAD: Canadian Dollar; HbA1c: Hemoglobin A1c; vs.: versus 
 Risk indicator is associated with an increase in the expected rate of NSH, adjusting for all other risk indicators included in the model  
 Risk indicator is associated with a decrease in the expected rate of NSH, adjusting for all other risk indicators included in the model 
 † The adjusted proportional odds ratio was 1.01 (95% CI: 0.59 to 1.71) 
Note: The strength of association for a risk indicator common to different types of NSH outcomes cannot be directly compared. 
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C. Nocturnal NSH 
D. Any NSH as an ordinal outcome  
 
Figure 2. Forest plots summarizing the adjusted estimates of association for significant risk 
indicators of: any NSH as a count outcome (A), daytime NSH (B), nocturnal NSH (C), and 
any NSH as an ordinal outcome (D). Asterisk (*) indicates the reference group. 
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Chapter 5  
5 Discussion and conclusion  
The purpose of this chapter is: 
1) To present an overview of this thesis and summarize the key results for Objectives 
1-3 (Section 5.1) 
2) To provide plausible explanations and contextualize results for Objectives 1-3 
(Section 5.2) 
3) To summarize the key results for Objective 4 and its methodological implications 
(Section 5.3) 
4) To discuss the strengths and limitations of this thesis (Sections 5.4 & 5.5)   
5) To provide a conclusion to this thesis, highlighting the implications of this work 
and suggesting directions for future research (Section 5.6) 
5.1 Thesis overview & summary of results for objectives 1 - 3 
A review of the literature to date has identified a paucity of research on NSH. Given that 
NSH is a predictor of SH3–5, there is a need to understand the risk indicators for NSH in 
order to minimize these events commonly experienced by individuals with T2DM using 
insulin and/or insulin secretagogues. Yet, the existing body of evidence has limited 
generalizability due to the use of randomized trials focused on highly-selective 
populations, clinical/ administrative records with poor documentation of NSH, and the 
disregard for individuals treated with secretagogues as a population at-risk for 
hypoglycemia.   
The InHypo-DM Study was a population-based, cross-sectional investigation of 
hypoglycemia among Canadian adults using insulin and/or secretagogues. Using self-
reported hypoglycemia data captured by the InHypo-DM Study, this thesis explored 
socio-demographic and clinical risk indicators associated with NSH in T2DM. To this 
end, this thesis was able to examine daytime NSH (i.e., events occurring during normal 
waking hours) and nocturnal NSH (i.e., events occurring during sleep/when attempting to 
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sleep) separately as the InHypo-DM Study captured information regarding time of 
occurrence for NSH. Such information is rarely available in the literature. 
There were four objectives in this thesis. Objective 1 focused on identifying risk 
indicators associated with the frequency of any NSH, which referred to a sum of daytime 
and nocturnal NSH events. Objective 2 aimed to identify risk indicators associated with 
the frequency of daytime NSH, defined as self-managed mild/moderate hypoglycemia 
that occurred during normal waking hours. Objective 3 was to identify risk indicators 
associated with the frequency of nocturnal NSH, defined as self-managed mild/moderate 
hypoglycemia that occurred as one was sleeping/attempting to sleep. Objective 4 sought 
to: a) to propose a set of categories that can be used to classify NSH frequency; then b) 
re-conduct Objective 1 where the dependent variable of ‘frequency of any NSH’ is 
regarded as an ordinal outcome (using the proposed categories) rather than a count 
outcome (as done in Objective 1). The purpose of this fourth objective was to enhance the 
clinical interpretation of results related to hypoglycemia occurrence. Categorizing data 
into clinically-relevant categories is a common approach used in clinical epidemiology 
and thus, applied to Objective 4.     
Analyses of the population-based data in this thesis confirmed the common and repeated 
occurrence of NSH among individuals with T2DM (Table 8). Over half of the 432 
individuals (53.9%, 95% CI: 49.2% to 58.6%) experienced at least one event of any NSH 
over the last 30 days. For daytime NSH, approximately half of all individuals had at least 
one event in the last 30 days. For nocturnal NSH, nearly one third of all individuals 
experienced at least one event in the same timeframe. On average, individuals with 
T2DM experienced 2.3 events of any NSH in the last 30 days (95% CI: 2.1 to 2.4 events 
per 30-person days) and when annualized, was equivalent to 27.5 events per person-year 
(95% CI: 25.8 to 29.3 events/person-year).  
To address the objectives of this thesis, multiple novel statistical methods were applied. 
Negative binomial regression models with backward variable selection were constructed 
to identify risk indicators associated with the past-30-day frequency of any NSH 
(Objective 1), daytime NSH (Objective 2), and nocturnal NSH (Objective 3). A 
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proportional odds regression model with backward selection was used to identify risk 
indicators for any NSH when frequency was regarded as an ordinal outcome (Objective 
4); for sensitivity analyses, a partial proportional odds regression model was used. 
Results for each outcome are summarized in Table 14. The risk indicators associated 
with an increased 30-day frequency of any NSH were: younger age, lower annual 
household income, being employed, longer duration of disease, higher HbA1c, and 
presence of comorbidity. The risk indicators associated with an increased 30-day 
frequency of daytime NSH were: younger age, lower annual household income, being 
employed, higher HbA1c, medication type, and presence of comorbidity. The risk 
indicators associated with an increased 30-day frequency of nocturnal NSH were: 
younger age, lower annual household income, higher HbA1c, and presence of 
comorbidity. Results for any NSH where frequency was regarded as an ordinal outcome 
will be summarized and discussed in Chapter 5.3. 
5.2 Interpreting risk indicators for NSH (Objectives 1 – 3) 
5.2.1 Risk indicators for any NSH 
This thesis investigated an array of potential risk indicators, some which have traditionally 
been examined and some that have not. Age is a risk indicator commonly considered in the 
literature. Yet, available evidence has largely pointed to a lack of association with 
NSH8,42,85,86. In this thesis, younger age was weakly associated with a higher incidence rate 
of any NSH among adults with T2DM. These results extend findings from a cross-
sectional study by Miller et al.81 that observed a slight association between younger age 
and the incidence proportion of any (i.e., non-severe or severe) hypoglycemia where SH 
was merely reported by 0.5% of participants. Our findings were also comparable to 
estimates relating age to the risk for NSH derived from a univariate NBR analysis of the 
Canadian cohort in the Hypoglycemia Awareness Tool study111. However, that study did 
comprise of adults with T1DM (37%) and T2DM (63%).   
Several plausible explanations exist for the relevance of younger age to NSH rates noted 
in this thesis. As previously suggested by Miller et al.81, younger individuals may have 
different lifestyle and behaviors that may induce hypoglycemia, such as increased 
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exercising or irregular eating patterns. On the other hand, age-specific differences may 
have influenced older respondents to underestimate their frequency of NSH as it was self-
reported in the InHypo-DMPQ. Changes in the symptomology of NSH2,112,113 and 
decreased hypoglycemia awareness114 have been observed with older age. But 
interestingly, when NSH was defined by a biochemical threshold of ≤3.0 mmol/L instead 
of self-reported symptoms in the ORIGIN trial, epidemiological analyses revealed that 
younger age was independently associated with NSH3.  
Prior to analyses conducted in this thesis, the author of this thesis was aware of literature 
suggesting a non-linear relationship between HbA1c and the risk for hypoglycemia. 
Analysis of data from the DISTANCE survey has suggested a U-shape relationship 
between HbA1c levels and the risk for severe hypoglycemia
115.  The DIALOG 
observational study noted a similar finding regarding the risk for any hypoglycemia 
among insulin-treated patients with T2DM83. Although this relationship was thought to 
be clinically plausible for NSH, univariable analysis of the data from the InHypo-DM 
Study did not support the existence of a non-linear, quadratic association. Hence, HbA1c 
was modelled as a linear variable in this thesis. Results indicated a positive association 
between HbA1c and the frequency of any NSH (IRR: 1.03, 95% CI: 1.01-1.06).  
Previous studies present conflicting evidence regarding the linear relationship between 
HbA1c and NSH. Secondary analyses of the ORIGIN trial noted that a higher baseline 
HbA1c was associated with NSH while the cross-sectional PANORAMA study of insulin-
treated patients with T2DM observed findings in the opposite direction3,42. Given the 
limited studies on NSH, literature on risk indicators for hypoglycemic events of any 
severity was examined to further contextualize the findings from this thesis. Again, the 
evidence is inconsistent8,71,77,88 though several studies have reported an independent 
association between increasing levels of HbA1c and a greater risk of SH
77,88. The 
association noted in this thesis may be explained by higher HbA1c reflecting poor 
glycemic control, which may have resulted in NSH79. Conversely, it is plausible that 
individuals with recurrent hypoglycemia were managed with less stringent glucose 
targets by healthcare providers or, intentionally self-maintained high blood glucose 
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levels35,58,59 as a preventative measure. Both approaches to management could have 
resulted in higher HbA1c.  
On the other hand, results in this thesis indicating a longer duration of diabetes and 
presence of comorbidities as independent clinical risk indicators for NSH are tenable. 
The association between a longer duration of diabetes and higher rates of NSH may 
reflect the progressive failure of beta cell function, where intensive therapy is 
increasingly needed. Comorbidity is known to negatively impact diabetes care by not 
only detracting from the prioritization of diabetes as a health concern, but also lowering 
one’s self-management abilities116,117. Thus, it is intuitive that having health conditions 
which hinder prevention/ treatment of hypoglycemia is associated with increased rates of 
NSH. Conversely, recurrent hypoglycemia may contribute to comorbidities, such as 
dementia118 or depression119,  that can impede management though specific conditions 
were not captured in the InHypo-DMPQ for pragmatic purposes. Rather, the lack of 
myopic focus on specific health conditions is an added strength as it acknowledges that 
comorbidities, both physiologically related or unrelated to diabetes, may act as barriers or 
competing demands to hypoglycemia management.  
Moreover, findings from this thesis highlight the relevance of social determinants of 
hypoglycemia. Prior risk factor studies on NSH accounted for education level and 
occupational status, likely as measures of socio-economic status, but did not consider 
annual household income42,85,86. However given the relevance of all three characteristics 
in measuring different aspects of socio-economic status120, this thesis also explored 
annual household income as well as education level and employment status. Results 
demonstrated a strong inverse dose-response relationship between annual household 
income and the increased rate of NSH, which paralleled findings for SH among 
individuals with T2DM121. This association bolsters qualitative observations noted in a 
Canadian study which suggested that although low-income adults with T2DM are aware 
of the importance of optimal diabetes management, they struggle to do so in practice due 
to financial constraints122. Such challenges may be mediated by food insecurity123–125, 
though further investigations in the context of NSH are needed.  
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Previously, studies that explored employment status as a potential risk indicator did not 
observe an association with NSH42,85,86. Interestingly, this thesis found that being 
employed was associated with higher rates of any NSH (IRR: 1.45, 95% CI: 1.01, 2.09). 
Although this association may appear counterintuitive to the aforementioned link 
between lower annual household income and higher rates of any NSH, it is important to 
recognize that all identified risk indicators were independently associated with NSH. 
Here, being employed may allude to the situational/psychosocial effects of working 
rather than the economic implications given that annual household income was adjusted 
for in the final multivariable models. The specific nature of the job and/or the workplace 
environment may not be conducive to optimal glycemic management. Barriers may 
include irregular meal times, skipping of meals, shiftwork, limited opportunities to 
monitor blood glucose, or stigma126. These challenges can hinder one’s ability to detect, 
resolve, and prevent hypoglycemia. Thus, further research on the impact of work-related 
situational/psychosocial factors on glycemic management and hypoglycemia is justified.  
5.2.2 Risk indicators for daytime and nocturnal NSH 
Detailed reporting of NSH based on time of occurrence (i.e., during waking hours versus 
when the respondent was asleep/attempting to sleep) in the InHypo-DMPQ provided the 
opportunity to investigate risk indicators for daytime and nocturnal NSH in this thesis. 
However, the direct comparison of evidence presented in this thesis with risk indicators 
for daytime or nocturnal NSH reported in the literature is limited given that such richness 
of information was seldomly collected in previous studies. In this thesis, several risk 
indicators identified for the increased rate of daytime NSH were consistent to the ones 
noted for any NSH and nocturnal NSH: younger age, lower annual household income, 
higher HbA1c, and presence of comorbidity (Table 14). The plausibility of these risk 
indicators was previously discussed in the context of any NSH in Chapter 5.2.1, but are 
also applicable to daytime NSH and nocturnal NSH. 
However, there were two discrepancies in the risk indicators identified for daytime NSH 
compared to nocturnal NSH. Being employed and type of diabetes medication were 
unique to daytime NSH and not observed for nocturnal NSH (Table 14). It is postulated 
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that employed individuals worked during the day, hence likely experienced daytime NSH 
while at work; a previous study of patients with T2DM in the United Kingdom observed 
that roughly 23% of employed individuals had an event while at work127. Although 
information regarding the location of hypoglycemia occurrence was not collected, the 
association of being employed with daytime NSH, but not nocturnal NSH supports this 
hypothesis. As previously discussed in Chapter 5.2.1, the psychosocial/situational 
aspects of the workplace may contribute to an increased rate of NSH. Furthermore, 
results indicating the association between medication type and the rate of daytime NSH 
was not surprising. Secretagogues and insulin regimens are often linked to mealtimes. 
Thus, behaviours, like skipping meals or daytime exercise, can induce NSH occurring 
during waking hours. Importantly, this thesis draws attention to the increased risk of NSH 
associated with individuals who were treated with a combination of insulin and 
secretagogues, providing real-world support to the mounting evidence from clinical 
trials128–130. 
5.3 Methodological discussion of categorizing NSH frequency 
(Objective 4) 
Hypoglycemia frequency treated as count outcome (i.e., number of events) distinguishes 
the occurrence of events as incremental one-unit increases. However, the clinical 
significance between differing number of events, especially a mere one-event difference 
in the context of frequently-occurring NSH, was debatable and had yet to be explored. 
Thus, Objective 4 aimed to propose frequency categories that may be used to classify the 
number of NSH events into clinically-different groups. Subsequently, this categorization 
was used to explore risk indicators associated with the frequency of any NSH, which was 
the same research question put forth by Objective 1 with the only difference being that 
the frequency of any NSH was considered as an ordinal outcome rather than a count 
outcome. This discussion will focus on: 1) comparing the results of significant risk 
indicators identified for any NSH when frequency of events was regarded as an ordinal 
outcome versus a count outcome; and 2) the methodological implications surrounding the 
consolidation of hypoglycemia frequency, a count outcome, into categories.  
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A PO model was used to identify risk indicators for any NSH regarded as an ordinal 
outcome in contrast to the NBR model used when the frequency of any NSH was treated 
as a count outcome. Here, the frequency of any NSH occurring in the past thirty days was 
defined by consolidating the number of hypoglycemia events into four categories: 0 
events (none); 1 event (once a month); 2-4 events (at least once biweekly but less than 
once a week); and ≥4 events (at least once a week). Consistent findings from Sensitivity 
Analysis #2 using a PPO model affirmed the validity of using a PO model. Risk 
indicators for any NSH identified by the PO model were largely consistent with results 
from the NBR model constructed in Objective 1, with the exception of only two 
differences (Table 14).   
The first discrepancy was the observed association between longer duration of diabetes 
and NSH in the NBR model (i.e., when frequency of NSH was regarded as a count 
outcome), but not the PO model (i.e., when frequency of NSH was regarded as an ordinal 
outcome). It is posited that duration of diabetes may have served as a proxy measure for 
the use of insulin/combination therapy in the NBR model as pancreatic beta cell function 
progressively declines with advancing T2DM. The second difference was the association 
of medication type observed in the PO model, but not the NBR model. Specifically, 
multivariable analysis revealed that the use of combination therapy (i.e., insulin and 
secretagogues) was associated with a notable increased rate of any NSH when compared 
to the use of secretagogues alone (IRR: 1.98, 95% CI: 1.20-3.27). Applying a similar 
logic, medication type may have been a proxy measure for duration of diabetes in the PO 
model. Alternatively, the use of categories in the PO model may suggest that medication 
type is more relevant to relative frequency of hypoglycemia (increasing from ‘no events’ 
to ‘once a month’ to ‘at least once biweekly but less than once a weekly’ to ‘at least once 
a week), which may be more clinically significant, rather than the absolute frequency in 
the NBR model.  
To the author’s knowledge, this thesis is the first foray into addressing this 
methodological challenge within the area of hypoglycemia. While some studies have 
categorized the frequency of hypoglycemia2,5,8,43,89,90, none were specifically undertaken 
for the purposes of investigating methodological issues. Furthermore, the rationale behind 
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the categories used in these previous studies were either driven by the distribution of the 
specific dataset, which limits the generalizability of results and future use of these 
categories, or was not explicitly detailed, though limited word counts in peer-reviewed 
publications may be the reason. The frequency categories for NSH proposed in this thesis 
was informed by clinical rationale, literature on previous categorizations used, and utility 
values for NSH elicited from Canadian adults with diabetes107 then corroborated with the 
distribution of the data for feasibility (i.e., whether particular categories had a reasonable 
number of observations to justify its use in regression analyses). Though hypoglycemia 
occurrence was measured as an absolute frequency in the InHypo-DMPQ, this thesis 
derived categories with ranges of absolute frequencies that may also be interpreted as 
relative frequencies. Previously, Henderson et al. measured the occurrence of NSH as a 
combination of absolute and relative frequencies: ‘never’, ‘1-2 episodes per year’, ‘4-12 
per year’, ‘one or more per month’, ‘one or more per week’, and ‘daily’2. However, recall 
of NSH up to one year may be difficult given the transient nature of events131. Of note, 
the relative frequencies of NSH analyzed in this thesis were not directly measured as such 
from the study population but derived from absolute frequencies collected by the InHypo-
DMPQ. Thus, results of this thesis may only provide empirical evidence for comparing 
hypoglycemia frequency as a count versus ordinal outcome from an analytical, but not 
measurement standpoint.  
Currently, the American Diabetes Association Workgroup on Hypoglycemia 
recommends that hypoglycemia frequency be descriptively reported as incidence 
proportions and rates in clinical trials38, thus implicitly stating the need to collect absolute 
frequencies of hypoglycemia (i.e., a count outcome). However, there may be value in 
measuring and/or analyzing hypoglycemia frequency as both a count and ordinal 
outcome to close the gap between statistical and clinical interpretation of results. 
Traditionally, the categorization of health data has enhanced the ease of clinical 
interpretations. Examples of this method in other chronic diseases include the categories 
for body mass index (i.e., ‘underweight’, ‘normal weight’, ‘overweight’, or ‘obese’)132 
and categories used to characterize the 10-year risk of coronary heart disease (ranging 
from ‘very low’ to ‘very high’) derived from the Framingham Risk Score13. By the same 
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token, creating a standardized set of categories to characterize hypoglycemia frequency 
may enhance clinical interpretation. Furthermore, it may be of interest to develop such 
consensus as the literature is fraught with different ways of categorizing hypoglycemia 
frequency2,5,8,43,89,90. Such heterogeneity limits the comparability and synthesis of 
evidence for hypoglycemia.  
Yet, it is important to acknowledge that the use of categories has its limitations. From a 
statistical standpoint, the grouping of counts into ordinal categories results in a loss of 
information regarding the distribution of data133. In the context of this thesis, this issue is 
particularly relevant to individuals who reported numerous events of NSH, representing 
counts on the high end of the frequency distribution. The highest frequency category for 
any NSH (i.e., ≥four events within the past 30 days, equivalent to ‘at least once a week’) 
would have included those who reported five events and those who reported twenty-five 
events. Consequently, these two experiences would have been considered as synonymous 
in the identification of risk indicators.    
5.4 Strengths 
The key strengths of this thesis are attributed to the pragmatic design of the InHypo-DM 
Study, affording the opportunity to address the risk indicators for NSH among individuals 
with T2DM in a real-world context. 
First, the inclusion of individuals with T2DM treated with insulin and/or secretagogues 
contributed to a more comprehensive study population reflecting those at risk of 
hypoglycemia than prior studies. Previous studies often used sampling frames which 
were either too narrow in scope, by focusing on insulin-treated adults with 
T2DM58,86,87,111,134,135, or conversely too broad, including individuals with T2DM who 
could solely be on diabetes medications that cannot induce hypoglycemia42,80,81,136. Thus, 
the study population examined in thesis enhances the generalizability of results.  
Second, ascertainment of hypoglycemia occurrence by the InHypo-DMPQ through self-
report in a non-clinical setting likely mitigated bias that would have been introduced by 
reliance on electronic medical records or administrative claims databases due to 
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underreporting and poor documentation in the clinical setting. These challenges are 
particularly relevant to capturing NSH as it is a self-managed event and that does not 
require assistance from medical personnel. Indeed, annualized incidence estimates of 
NSH from a meta-analysis of studies that recruited patients with T2DM from clinical 
settings were slightly lower than estimates reported in this thesis12.  
Third, the pragmatic definition of hypoglycemia used in the InHypo-DMPQ framed 
around the presence of physical symptoms and extent of required management solidified 
NSH as a true patient-reported outcome. In contrast, NSH occurrence solely defined by a 
blood glucose value is a surrogate outcome. Moreover, there is a wide heterogeneity in 
the threshold level of blood glucose used to define NSH among studies requiring 
biochemical confirmation, varying from <2.8 mmol/l to ≤3.8 mmol/l41,81,85. Thus, the 
definition used in the InHypo-DMPQ mitigated variability in the reported frequency of 
hypoglycemia which would have been dependent on the specific blood glucose cutoff 
used128.  
5.5 Limitations 
This thesis has several limitations. First, definitive causal inferences cannot be made 
between the identified risk indicators and NSH given the cross-sectional design of the 
InHypo-DM Study. Hence, the term “risk indicator” was used in this thesis to encompass 
the potential for identified characteristics to be causally related factors (i.e., risk factors) 
or non-casually related but associated factors (i.e., risk markers)69. Temporality of the 
risk indicators and NSH occurrence could not be established though it is highly plausible 
that certain socio-demographic and clinical characteristics, such as age (in years), annual 
household income, duration of diabetes (in years), and HbA1c level would have remained 
consistent had they been collected prior to the thirty-day recall period for NSH. 
Nevertheless, reverse causality cannot be dismissed.  
Second, recall bias may have been introduced as the InHypo-DMPQ is a self-reported 
measure. However, the selected recall period of 30 days for NSH was designed to 
minimize such bias. It was chosen in consultation with clinical expertise, guidelines for 
patient-reported outcomes published by the Food and Drug Administration73, and 
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subsequently validated among individuals with diabetes during the pilot testing of the 
InHypo-DMPQ. Furthermore, similar recall periods for self-reported NSH have also been 
used in previous studies59,60,86,87. Regarding the recall of socio-demographic and clinical 
characteristics, the wording of these items and their associated response formats on the 
InHypo-DMPQ were also designed with a pragmatic intent to minimize respondent 
burden and encourage accurate reporting. For example, possible responses to annual 
household income were provided as income brackets. Additionally, the use of medical 
jargon was kept to a minimum and phrased in layman’s terms when possible. For 
example, comorbidities and oral glucose-lowering therapies were referred to as “health 
conditions” and “pills for lowering blood sugar”, respectively. When a colloquial term 
was not available, respondents were provided with a practical definition, as in the case of 
HbA1c and NSH. Furthermore, a time limit was not imposed for the completion of the 
InHypo-DMPQ, giving respondents the opportunity to verify responses with personal 
records.   
Although the merits of defining NSH as a patient-reported outcome were previously 
discussed, the lack of biochemical confirmation required by self-monitoring of blood 
glucose may have underestimated the occurrence of asymptomatic events31. 
Reassuringly, incidence estimates from this thesis are highly comparable to those in a 
real-world study of individuals with T2DM, similarly recruited from an online panel, 
where self-reported NSH was defined as both a symptomatic event or an asymptomatic 
event with a blood glucose measurement of ≤ 3.1 mmol/L135.  
Fourth, the use of an online panel may have imposed selection bias on the participants 
selected into the study. It may have resulted in a greater representation of younger 
individuals and undercoverage of those who do not have internet access, did not have 
prior membership in the online panel, or with limited digital literacy. Lastly, the risk 
indicators explored in this thesis were confined to items collected in the InHypo-DMPQ. 
However, items included in the InHypo-DMPQ were based on an extensive literature 
review of existing measures for glycemic management, clinical/methodological expertise, 
and validated for face and content validity by individuals with diabetes.  For this thesis, 
the selection of socio-demographic/clinical characteristics from the InHypo-DMPQ as 
 61 
 
potential risk indicators was informed by clinical plausibility, literature/clinical 
guidelines on risk indicators for hypoglycemia, and methodological considerations to 
whether inclusion of multiple variables were thought to represent the same latent 
construct, as previously discussed in Chapter 3.2.15. 
5.6 Conclusion  
Non-severe hypoglycemia is a common adverse event resulting from the use of insulin 
and/or insulin secretagogues for T2DM. Hypoglycemia poses as a challenge to diabetes 
management as it deters medication adherence, intensification of treatment, and impairs 
self-awareness of future episodes. Yet with such substantial ramifications, there is a 
paucity of research towards characterizing the occurrence and associated risk indicators 
for NSH. Furthermore, the generalizability of the limited evidence available is confined 
by the strict inclusion criteria employed by clinical trials and an underestimation of 
events in studies using clinical databases, such as electronic medical records/claims 
records.  
This thesis contributed real-world, epidemiological evidence to identify risk indicators 
for NSH in T2DM. Results highlight the role of social and clinical determinants. These 
findings may help identify patients at risk of high rates of NSH, enabling opportunities to 
minimize NSH and enact upstream prevention of SH with the ultimate goal of improving 
diabetes management. Using data from the largest population-based study of 
hypoglycemia in Canada to date, this thesis also confirmed the common and repeated 
real-world occurrence of NSH among individuals with T2DM. Additionally, this thesis 
acknowledged the methodological and analytical challenges surrounding hypoglycemia 
research. In doing so, this body of work hopes to spur future methodological discussions 
and considerations contextualized to hypoglycemia, as previously done in sex133 and 
alcohol research137. The novel set of frequency categories proposed may serve as a 
precedent to future methodological research in this area.  
Several directions for future research are envisioned. First, further analyses could be 
conducted by modeling daytime NSH and nocturnal NSH as bivariate outcomes to 
simultaneously investigate the difference and commonality of risk indicators. These 
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analyses will build upon insight presented by this thesis where risk indicators were 
independently identified for daytime NSH and nocturnal NSH through two separate 
models. Second, exploring behavioural characteristics are warranted to further understand 
the determinants influencing hypoglycemia and its management. Although this thesis was 
exploratory, socio-demographic and clinical risk indicators are more distal and likely 
mediated by behavioural factors along the causal pathway to hypoglycemia.   
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Appendices 
Appendix A. A selection of key observational studies that investigated risk factors for hypoglycemia (any severity) among individuals 
with diabetes 
Study Study 
Population 
Definition of hypoglycemia for which risk factors 
were identified 
Study Period Data Type†  
(Type of statistical 
analysis used) 
HAT Study60 Adults with 
T1DM or T2DM 
on insulin 
Any hypoglycemia: included non-severe 
hypoglycemia (self-managed), severe hypoglycemia 
(requiring third-party assistance), nocturnal 
hypoglycemia (occurring between midnight and 
06:00) 
SH: 6 months 
retrospective, 
4 weeks 
prospective NSH: 4 
weeks retrospective 
and prospective 
 
Count 
(NBR) 
International 
Operations 
HAT Study82  
(2nd wave of 
HAT Study 
conducted in 
different 
countries) 
Fremantle 
Diabetes 
Study88 
Adults with 
T1DM or T2DM 
Severe hypoglycemia: an episode in which a patient 
with a subnormal blood/plasma/serum glucose 
required health service use and hypoglycemia was 
the primary diagnosis 
January 1999 to 
June 2006  
Count  
(Poisson, NBR, 
ZIPR, ZINBR) 
PREDICTIVE 
Study84 
Adults with 
T1DM or T2DM 
on insulin 
detemir 
Hypoglycaemic episode: An episode with one of the 
following characteristics: 
· Symptoms of hypoglycaemia that resolve with oral 
carbohydrate intake, glucagon or intravenous glucose 
· Any symptomatic or asymptomatic blood glucose 
<2.8 mmol/l (50 mg/dl) 
Nocturnal hypoglycaemic episodes: Individualized 
symptomatic episodes consistent with hypoglycaemia 
that occur while asleep, between bedtime after the 
evening insulin injection and before getting up in the 
morning (before morning determination of fasting 
glucose and morning injection) 
4 weeks Count 
(NBR) 
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Major hypoglycaemic episodes: Severe central 
nervous system symptoms consistent with 
hypoglycaemia in which the subject is unable to treat 
himself/herself and third-party intervention is needed 
and has one of the following characteristics: 
· Blood glucose <2.8 mmol/l (50 mg/dl) 
· Reversal of symptoms after food intake, glucagon 
or intravenous glucose 
DIALOG 
Study83 
Insulin-treated 
adults with 
T1DM and 
T2DM 
Confirmed hypoglycemia: included severe 
hypoglycemia (requiring third-party assistance), 
documented symptomatic hypoglycemia (typical 
symptoms, plasma glucose value <3.9 mmol/L, self-
treated), and asymptomatic hypoglycemia (absence 
of typical symptoms, plasma glucose value <3.9 
mmol/L) as defined by 2005 ADA guidelines 
30 days 
prospective, 
1 year retrospective 
(for SH) 
Count 
(Logistic 
regression*) 
DiaRegis 
Study79 
Patients with 
T2DM 
Any hypoglycemia: not specified however 
distinguished between: (1) whether help was required 
(medical or non-medical period or leading to 
hospitalization) and (2) whether or not it was 
symptomatic 
24 months 
prospective 
Count 
(Logistic 
regression*) 
PANORAMA 
Study42 
Adults with 
T2DM 
Severe hypoglycemia: an episode requiring external 
assistance, with prompt recovery after glucose or 
glucagon administration 
Non-severe hypoglycemia: an episode that did not 
require external assistance 
SH: 1 year 
retrospective 
NSH: 1 month or 1 
year retrospective  
Count 
(Logistic 
regression*) 
GAPP2 Study86 Adults with 
T2DM using 
basal insulin 
Non-severe hypoglycemia: symptoms of low blood 
sugar that could be self-treated 
30 days Count 
(Chi-squared 
Automatic 
Interaction 
Detection analysis) 
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Gu et al.87   Patients with 
T2DM on a 
basal-bolus 
regimen 
Mild hypoglycemia: one or more episodes of 
hypoglycemia with symptoms (e.g., palpitations, 
hunger, sweating, tremulousness, weakness, fatigue, 
dizziness, and anxiety) 
1 month 
retrospective 
Binary 
(Logistic 
regression with 
restricted cubic 
splines) 
Donnelly et al.8  Patients with 
T1DM and 
insulin-treated 
T2DM  
An aggregate of mild hypoglycemia (self-reported, 
symptomatic event that did not require third-party 
assistance) and severe hypoglycemia (required third-
party assistance) 
1 month 
prospective 
Ordinal categories: 
T1DM: 0, 1, 2, 3, 
≥4 events 
T2DM: 0, 1, 2, 3 
events 
(Proportional odds 
regression) 
†Refers to how hypoglycemia occurrence was treated in analysis, but not necessarily how it was measured during data collection  
*Measured as a count outcome (i.e., absolute frequency), but analyzed as a binary outcome (0 vs. ≥1 event) when identifying risk 
factors 
Abbreviations: NBR: negative binomial regression; T1DM: Type 1 Diabetes Mellitus; T2DM: Type 2 Diabetes Mellitus; ZIPR: zero-
inflated poisson regression; ZINBR: zero-inflated negative binomial regression 
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Appendix B. Comparison of demographic characteristics of Canadian panelists maintained by 
Ipsos Interactive Services Ltd. to results from the 2011 National Household Survey. Table 
provided by Ipsos Interactive Services Ltd. 
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Appendix D. Comparison of characteristics of the thesis sample and InHypo-DM Study 
respondents to the general diabetes population in Canada. 
 
Canadian population 
with diabetes 
InHypo-DM 
Respondents45 
Thesis 
Sample 
Individuals with diabetes (≥18 yrs) N = 2,065,500* N = 552 N = 432 
Gender    
   Male 56.0%* 56.0% 56.2% 
   Female 44.0%* 44.0% 43.8% 
Age (years)    
 
 
   18 – 34 3.5%* 17.8% 14.4% 
   35 – 49  14.9%* 22.3% 21.5% 
   50 – 64  34.6%* 36.8% 38.2% 
   ≥ 65 47.0%* 23.2% 25.9% 
Has Drug Coverage 85.0%† 90.6% 91.0% 
*Canadian Community Health Survey 2015138 
†Survey on Living with Chronic Diseases 2011, as reported in Diabetes Canada’s 2015 Report on 
Diabetes: Driving Change138 
Note: It was not possible to make comparisons to the general diabetes population in Canada who 
specifically have T2DM and are treated with insulin and/or secretagogues as such data is not 
available. However, individuals with T2DM do account for 90% of the general diabetes population in 
Canada139. 
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Appendix E. InHypo-DM Patient Questionnaire (abridged version including items 
relevant to this thesis) 
Investigating Hypoglycemia: Your Perspectives on Diabetes 
Management Questionnaire 
(InHYPO-DMPQ) 
Everyone with diabetes experiences hypoglycemia now and then.  The following series of 
questions will explore your thoughts, feelings, beliefs, and actions around hypoglycemia 
and its management. Please be as honest and accurate as possible. There are no correct 
answers. We are interested in your opinion. There are 11 sections in total. You may refuse 
to answer any question you do not want to answer. All responses will be kept completely 
confidential. 
 
 
PLEASE READ BEFORE STARTING: 
Questions will apply to both the treatment (acute) and prevention (chronic) of 
hypoglycemia. We will refer to this as hypoglycemia management, unless specified.   In 
addition, questions will refer to all “types” of hypoglycemia: mild or moderate as well as 
severe hypoglycemia.  Please refer to the definitions provided below, which describe each 
of these “types” of hypoglycemia. 
Mild or moderate hypoglycemia: When you have symptoms of hypoglycemia such as 
sweatiness, hunger, anxiety, weakness, confusion, heart palpitations, difficulty speaking, 
and/or lose your train of thought, but you are still able to take action yourself to reverse 
these symptoms (for example by drinking a glass of juice, eating something, or taking 
a sugar pill). 
Severe hypoglycemia: When you absolutely need assistance from someone else because 
you are either unable to help yourself or you are not aware that you need help. 
Also, healthcare providers will refer to any care provider who helps you manage your 
diabetes.  Examples may be family physicians, diabetes specialists, diabetes educators, 
dieticians, nurses, nurse practitioners, and/or pharmacists. 
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SECTION 11  
This section contains questions related to your background, diabetes management, and 
experience with hypoglycemia events.  Remember that management refers to treatment and 
prevention.   
 
1. Duration of diabetes (years): _________ 
2. What are your current living arrangements? 
 
 
 
 
 
 
3. As best you remember, what is your most recent HBA1c (also known as A1c) value?  
HBA1c is an average measure of your blood sugar over 3 months that is taken as part of 
your laboratory tests. 
 
 
Value: 
  
Test date: 
  
   
MM          YY 
 
 
4. Who pays the majority or all of your insulin and/or pills for lowering blood sugar? 
(Please check one box.) 
 
  
 
5. Who pays the majority or all of your blood sugar testing strips? (Please check one box.) 
  
  
 
6. What type of drug coverage do you have?  
 
  
 
 
 
 
Live alone   
Live with spouse/significant other   
Live with family member(s)   
Live with roommate/boarder   
Other, please specify: __________________   
My insurance company   
The government   
I pay for them myself   
My insurance company   
The government   
I pay for them myself   
None   
Provincial drug benefit   
Third Party (ex. private or work coverage)   
Other, please specify: __________________   
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7. Please indicate the type of healthcare provider from whom you receive the majority of 
your diabetes care: (Please check on box.) 
Family physician   
Nurse practitioner   
Endocrinologist   
Pharmacist   
Other, please specify: _________________   
 
8. Please identify your highest level of education: (Please check one box.)  
Elementary school   
High school   
CEGEP   
Technical school or College   
University   
Graduate/Professional school   
 
9. Please identify your current employment status: (Please check all that apply.)  
Working full time   
Working part time or Seasonal   
Unemployed   
Student   
Stay-at-home parent   
Disability   
Retired   
 
10. If you are employed, what is your current occupation? 
________________________________________ 
 
11. If you are employed, do you work shifts?  
Yes   
No   
 
12. Please identify your approximate annual household income: (Please check one box.) 
<$30,000   
$30,000-$50,000   
$51,000-$75,000   
>$75,000   
 
13. How many injections of insulin a day do you administer? (Please answer times per day) 
1 time per day   
2 times per day   
3 times per day   
4 or more times per day   
I use an insulin pump   
I do not take insulin   
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14. Are you currently using a continuous glucose monitoring (CGM) device? 
 
Yes   
No   
 
15. Do you have other health conditions that get in the way of your management of your 
hypoglycemia? 
 
Yes   
No   
 
17. In the last 30 days, approximately how many times did you experience a mild or 
moderate hypoglycemia [programing of definition to appear: Mild or moderate 
hypoglycemia: When you have symptoms of hypoglycemia such as sweatiness, hunger, 
anxiety, weakness, confusion, heart palpitations, difficulty speaking, and/or lose your 
train of thought but you are still able to take action yourself to reverse these symptoms 
(for example by drinking a glass of juice, eating something, or taking a sugar  pill)] 
event that occurred during normal waking hours? (Please type the number of events 
in the box below.)                                                                                             
               Event(s) 
 
18. In the last 30 days, approximately how many times did you experience a mild or 
moderate hypoglycemia [programing of definition to appear: Mild or moderate 
hypoglycemia: When you have symptoms of hypoglycemia such as sweatiness, hunger, 
anxiety, weakness, confusion, heart palpitations, difficulty speaking, and/or lose your 
train of thought but you are still able to take action yourself to reverse these symptoms 
(for example by drinking a glass of juice, eating something, or taking a sugar pill)]  
event that occurred while sleeping/attempting to sleep? (Please type the number of 
events in the box below.)                                                                                                              
               Event(s) 
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Appendix F. Empirical logit plots generated for each candidate risk indicator using the 
Empirical Logit Plot SAS Macro. 
 
Each box represents one of the twelve candidate risk indicators (QA = duration of 
diabetes, QC_1_N = most recent HbA1c, QO = comorbidity status, drugcov = drug 
coverage, edu = education level, gender = gender, income = annual household income, 
livarr = living arrangements, med = medication type, resp_age = age, special = main 
healthcare provider, work = employment status).  Green, red, and blue lines denote the 
empirical logits for a cutoff-point of: ‘≤4’ vs. ‘>4’ events of any NSH; '0 and 1 and 2 to 4' 
vs. ‘>4’ events of any NSH; and ‘0 vs. ≥ 1’ event(s) of any NSH, respectively. For each 
candidate risk indicator, the assumption of proportional odds is satisfied if the three 
coloured lines are parallel. The dashed circles indicate risk indicators deemed to have 
mildly violated the assumption of proportional odds (i.e., the three coloured lines were 
not parallel). 
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Appendix G. Sensitivity Analysis #1 for any NSH (Objective 1) 
  Univariable Analysis Multivariable Analysis†  
Risk Indicators 
Crude 
IRR 
95% CI p-value 
Adjusted 
IRR 
95% CI p-value 
Age (per 1-year increase) 0.96 0.96 0.97 <0.001 0.97 0.96 0.98 <0.001 
Gender (Female vs. Male*) 0.89 0.65 1.23 0.49 - - - - 
Annual Household Income (CAD)       0.002       <0.001 
   $30,000 to 50,000 vs. <$30,000* 0.88 0.56 1.36   0.79 0.54 1.15   
   $51,000 to 75,000 vs. <$30,000* 0.67 0.43 1.05 0.50 0.33 0.75 
   >$75,000 vs. <$30,000* 0.46 0.30 0.69 0.39 0.26 0.57 
Education Level   
  
0.37   
   
   CEGEP/Technical School/College vs. Elementary/High School* 0.75 0.50 1.12   - - - - 
   University/Graduate/Professional School vs. Elementary/High School* 0.88 0.59 1.31 - - - - 
Living Alone (vs. Other*) 0.91 0.65 1.28 0.59 - - - - 
Employment Status (Working vs. Other*) 1.81 1.33 2.47 <0.001 1.56 1.10 2.20 0.01 
Drug Coverage (Yes vs. No*) 0.55 0.33 0.94 0.02 - - - - 
T2DM Duration (per 1-year increase) 1.01 0.99 1.03 0.51 1.02 1.00 1.04 
 
HbA1c (per 1% increase) 1.07 1.04 1.10 <.0001 1.03 1.01 1.06 0.002 
Medication Type   
  
0.07   
  
0.03 
   Insulin alone vs. Secretagogues alone* 0.89 0.62 1.27   1.48 1.08 2.04 
 
  Combination (Insulin and Secretagogues) vs. Secretagogues alone* 1.48 0.96 2.26 1.39 0.97 2.01 
  Combination (i.e., Insulin and Secretagogues) vs. Insulin alone* 1.67 1.06 2.61  0.94 0.63 1.39  
Presence of Comorbidities (vs. Absence*) 2.76 1.96 3.87 <0.001 2.24 1.66 3.02   
Main Healthcare Provider (Specialist vs. No Specialist*) 0.81 0.52 1.27 0.37 - - - - 
*Reference group 
†All risk indicators selected for inclusion into the final multivariable model through backward selection are listed   
Abbreviations: CAD: Canadian Dollar; CI: Confidence Interval, HbA1c: Hemoglobin A1c; IRR: Incidence Rate Ratio; vs.: versus 
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Appendix H. Sensitivity Analysis #1 for daytime NSH (Objective 2)                         
  Univariable Analysis Multivariable Analysis†  
Risk Indicators 
Crude 
IRR 
95% CI p-value 
Adjusted 
IRR 
95% CI p-value 
Age (per 1-year increase) 0.97 0.96 0.98 <0.001 0.98 0.97 0.99 <0.001 
Gender (Female vs. Male*) 0.99 0.74 1.32 0.93 - - - - 
Annual Household Income (CAD)       0.04       <0.001 
   $30,000 to 50,000 vs. <$30,000* 1.02 0.68 1.52   0.58 0.39 0.86   
   $51,000 to 75,000 vs. <$30,000* 0.88 0.58 1.32 0.41 0.27 0.63 
   >$75,000 vs. <$30,000* 0.60 0.41 0.89 0.35 0.23 0.52 
Education Level   
  
0.64   
  
- 
   CEGEP/Technical School/College vs. Elementary/High School* 0.84 0.58 1.21   - - - 
 
   University/Graduate/Professional School vs. Elementary/High School* 0.92 0.64 1.32 - - - 
Living Alone (vs. Other*) 1.12 0.82 1.53 0.49 - - - - 
Employment Status (Working vs. Other*) 1.76 1.32 2.34 <0.001 1.43 1.002 2.03 0.049 
Drug Coverage (Yes vs. No*) 0.58 0.36 0.92 0.02 - - - - 
T2DM Duration (per 1-year increase) 1.00 0.98 1.02 0.83 - - - - 
HbA1c (per 1% increase) 1.06 1.03 1.08 <0.001 1.03 1.00 1.05 0.03 
Medication Type   
  
0.02   
  
<0.001 
   Insulin alone vs. Secretagogues alone* 0.97 0.70 1.35   1.42 1.03 1.97 
 
  Combination (i.e., Insulin and Secretagogues) vs. Secretagogues alone* 1.64 1.13 2.40 1.80 1.26 2.58 
  Combination (i.e., Insulin and Secretagogues) vs. Insulin alone* 1.69 1.13 2.52  1.25 0.85 1.85  
Presence of Comorbidity (vs. Absence*) 2.58 1.91 3.49 <0.001 2.16 1.60 2.92 <0.001 
Main Healthcare Provider (Specialist vs. No Specialist*) 2.58 1.91 3.49 <0.001 - - - - 
*Reference group 
†All risk indicators selected for inclusion into the final multivariable model through backward selection are listed   
Abbreviations: CAD: Canadian Dollar; CI: Confidence Interval, HbA1c: Hemoglobin A1c; IRR: Incidence Rate Ratio; vs.: versus 
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Appendix I. Sensitivity Analysis #1 for nocturnal NSH (Objective 3) 
  Univariable Analysis Multivariable Analysis†  
Risk Indicators 
Crude 
IRR 
95% CI p-value 
Adjusted 
IRR 
95% CI p-value 
Age (per 1-year increase) 0.95 0.94 0.96 <0.001 0.95 0.94 0.97 <0.001 
Gender (Female vs. Male*) 0.82 0.52 1.30 0.39 - - - - 
Annual Household Income (CAD)       <0.001       <0.001 
   $30,000 to 50,000 vs. <$30,000* 0.78 0.42 1.44   0.74 0.44 1.23   
   $51,000 to 75,000 vs. <$30,000* 0.50 0.27 0.94   0.49 0.28 0.83 
   >$75,000 vs. <$30,000* 0.29 0.16 0.53   0.30 0.18 0.51 
Education Level   
  
0.39     - 
   CEGEP/Technical School/College vs. Elementary/High School* 0.68 0.38 1.21 
 
- - - 
 
   University/Graduate/Professional School vs. Elementary/High School* 0.90 0.51 1.60 - - - 
 
Living Alone (vs. Other*) 0.75 0.46 1.22 0.24 - - - - 
Employment Status (Working vs. Other*) 1.86 1.18 2.92 0.007 1.43 1.002 2.03 0.049 
Drug Coverage (Yes vs. No*) 0.48 0.23 1.01 0.05 - - - - 
T2DM Duration (per 1-year increase) 1.00 0.98 1.03 0.79 1.03 1.002 1.06 0.04 
HbA1c (per 1% increase) 1.10 1.06 1.13 <0.001 1.05 1.03 1.08 <0.001 
Medication Type   
  
0.01   
  
- 
   Insulin alone vs. Secretagogues alone* 0.51 0.30 0.85 
 
- - - 
 
   Combination (i.e., Insulin and Secretagogues) vs. Secretagogues alone* 1.29 0.71 2.33 
 
- - - 
   Combination (i.e., Insulin and Secretagogues) vs. Insulin alone* 2.54 1.33 4.84  - - -  
Presence of Comorbidities (vs. Absence*) 3.26 2.02 5.27 <0.001 2.30 1.55 3.42 <0.001 
Main Healthcare Provider (Specialist vs. No Specialist*) 0.61 0.31 1.18 0.14 - - - - 
*Reference group 
†All risk indicators selected for inclusion into the final multivariable model through backward selection are listed 
 
   
Abbreviations: CAD: Canadian Dollar; CI: Confidence Interval, HbA1c: Hemoglobin A1c; IRR: Incidence Rate Ratio; vs.: versus 
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Appendix J. Results from Sensitivity Analysis #2 from the multivariable partial proportional odds model for any NSH† 
Risk Indicators 
ORProp/ 
OR 
95% CI p-value 
Age (per 1-year increase) 0.97 0.95 0.98  <0.001 
Annual Household Income (CAD)   
  
0.004 
   $30,000 to 50,000 vs. <$30,000* 1.00 0.59 1.72 
 
   $51,000 to 75,000 vs. <$30,000* 0.60 0.34 1.05 
 
   >$75,000 vs. <$30,000* 0.43 0.25 0.73 
 
Work (Employed vs. Other) 1.63 1.01 2.63 0.046 
HbA1c (per 1% increase)   
  
0.006 
   ≥ "1 event" vs. "0 events"* 1.03 1.00 1.08 
 
   ≥ "2 to 4 events" vs. "1 event or 0 events"* 1.05 1.01 1.09 
 
   ≥ "4 events" vs. "2 to 4 events, or 1 event, or 0 events"* 1.06 1.02 1.10 
 
Medication Type       0.02 
   Insulin alone vs. Secretagogues Alone* 1.48 0.98 2.24 
 
   Combination vs. Secretagogues Alone* 1.99 1.21 3.28 
   Combination vs. Insulin Alone* 1.34 0.80 2.26  
Presence of Comorbidities (vs. Absence*) 2.44 1.58 3.77 <0.001  
Score Test χ2,11 = 103.82 p<0.001  
*Reference group 
    
†All risk indicators selected for inclusion into the final multivariable model through backward 
selection are listed 
Abbreviations: CAD: Canadian Dollar; HbA1c: Hemoglobin A1c; ORProp: Proportional Odds Ratio;    
vs.: versus 
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